

Parkinson's Europe

England & Wales · Charity number 1163211

Details

Other names	EUROPEAN PARKINSON'S DISEASE ASSOCIATION, EPDA, Parkinson's Europe
Status	Registered
Legal form	CIO
Registered	2015-08-19
Register	View on the Charity Commission register

Contact

Address
Baxter & Co
Lynwood House
2-4 Crofton Road
Orpington
Kent
BR6 8QE

Phone + 44 7928 051719

Email info@parkinsonseurope.org

Website www.parkinsonseurope.org

Activities

Objects: TO PROMOTE AND PROTECT THE PHYSICAL AND MENTAL HEALTH OF THOSE SUFFERING FROM PARKINSON'S DISEASE, IN PARTICULAR BUT NOT LIMITED TO THE FOLLOWING:-1) TO CHALLENGE EXISTING MIND-SETS, SHIFT ATTITUDES AND REMOVE THE HURDLES THAT PREVENT PEOPLE WITH PARKINSON'S FROM RECEIVING EARLY AND APPROPRIATE TREATMENT AND INDIVIDUALISED CARE; 2) TO INCREASE PUBLIC AND POLITICAL AWARENESS OF PARKINSON'S; AND 3) TO HELP REDUCE STIGMA AND REMOVE DISCRIMINATION AGAINST PEOPLE WITH PARKINSON'S.

Activities: Membership Association

Classification

- **How:** Provides Advocacy/advice/information, Sponsors Or Undertakes Research, Acts As An Umbrella Or Resource Body
- **What:** General Charitable Purposes, Education/training, The Advancement Of Health Or Saving Of Lives
- **Who:** Other Charities Or Voluntary Bodies, Other Defined Groups

Geography

- Belgium
- Croatia
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- France
- Germany
- Greece
- Hungary
- Ireland
- Israel
- Italy
- Luxembourg
- Netherlands
- Norway
- Poland
- Portugal
- Slovenia
- Spain
- Switzerland
- Ukraine
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2024-12-31	£503,694	£424,044	£198,854	6
2023-12-31	£578,064	£570,864	£93,405	6
2022-12-31	£324,364	£575,003	-	-
2021-12-31	£605,978	£564,491	£347,244	3
2020-12-31	£559,965	£519,668	£335,247	2

Trustees

Name	Role	Appointed
Josefa Maria Malta Domingos	Chair	2020-11-10
Antonella Moretti		2021-06-29
Brian John Magennis		2023-06-27
Cathy Molohan		2024-06-26
Claire Bale		2024-06-26
Elisabeth Ildal Nielsen		2024-06-26
Gary Boyle		2021-06-29
Janette Sinclair		2024-06-26

Accounts

Charity registration number 1163211

Company registration number CE004367 (England and Wales)

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

PARKINSON'S EUROPE

(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	G Boyle	
	J M M Domingos	
	C P Likar	
	A Moretti	
	A S Butler	
	B J Magennis	
	K Wouters	
	J Sinclair	(Appointed 26 June 2024)
	E Ildal	(Appointed 26 June 2024)
	C Molohan	(Appointed 26 June 2024)
	C Bale	(Appointed 26 June 2024)
Key Personnel	Rusell Patten	Director General
	Dominic Graham	Operations Director
	Lisa Wong	Finance Manager
Charity number	1163211	
Company number	CE004367	
Registered office	Lynwood House	
	Crofton Road	
	Orpington	
	Kent	
	BR6 8QE	
Independent examiner	Louise Hallsworth, FCA	
	Baxter & Co	
	Chartered Accountants	
	Lynwood House, Crofton Road	
	Orpington	
	Kent	
	BR6 8QE	

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) CONTENTS

	Page
Trustees' report	1 - 7
Independent examiner's report	8
Statement of financial activities	9 - 10
Balance sheet	11
Notes to the financial statements	12 - 20

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 31 DECEMBER 2024

The trustees present their annual report and financial statements for the year ended 31 December 2024.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's constitution, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019).

Objectives and activities

The objectives are to promote and protect the physical and mental health of those suffering from Parkinson's disease. In particular, but not limited to the following:

- 1) to challenge existing mind-sets, shift attitudes and remove the hurdles that prevent the people with Parkinson's from receiving early and appropriate treatment and individualised care;
- 2) to increase public and political awareness of Parkinson's;
- 3) to help reduce stigma and remove discrimination against people with Parkinson's.

Public benefit

The trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

Achievements and performance

Significant activities and achievements against objectives

Our New Four-Year Strategy (2025-2028)

In 2024, we were at the end of our previous (2019-2024) strategy window. Through evaluating all the data we had collected about the needs and wants of our stakeholders, we decided we needed a significant overhaul of the old strategy. The purpose was to really focus and deliver on what our stakeholders had told us they wanted.

The new strategy development started in February 2024, but the collection and review of supporting data had been ongoing since 2022, and involved internal and external stakeholders from the Parkinson's community. Our new four-year strategy was launched in January 2025 and is available via our website in five languages.

World Parkinson's Day 2024

Every year, World Parkinson's Day (WPD) on 11 April provides us with a unique opportunity to capture the world's attention with a far greater impact than usual. As founders of World Parkinson's Day, we feel it's our responsibility to lead the way, creating one of the biggest campaigns globally to create awareness and shine a spotlight on the needs of people with Parkinson's – as well as supporting and amplifying our Member Organisations' campaigns to a wider audience.

We decided this year to create a campaign that would prolong this global impact far beyond WPD itself, using the day to launch a six-month campaign we called the Parkinson's Summer of Sport. This campaign was about raising awareness of the benefits of exercise for people with Parkinson's, helping people to find an exercise that's right for them, and giving advice on overcoming exercise barriers.

Parkinson's Engagement Network

Parkinson's Europe recognised the need to reach more people across Europe in a strategic and constructive way, to share calls to action that would help us achieve our current and future strategic activities and support the many significant advancements for the Parkinson's community that are continually taking place in different areas. Built with financial support from our partner IQVIA and launched in December 2023, the PEN is an online network designed to involve people from Europe (and beyond) in Parkinson's-related activities. The PEN will help communicate better about Parkinson's opportunities to people interested and help get more people involved.

PARKINSON'S EUROPE

(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

Our Attendance at Events, Panels and Symposiums

Attending international events, congresses, panels and symposiums has always been a key priority for Parkinson's Europe. In 2024, our President Josefa Domingos, our Director General Russell Patten and our Strategic Director Amelia Hursey attended the following events:

- International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD), Lisbon, Portugal, March 2024 – attendee and speaker
- Ace Clinical Trials Summit, London, UK, March 2024 – speaker and session chair
- Digital Health @ Reuters Events: Pharma 2024, Barcelona, Spain, April 2024 – co-presenting session
- European Patients' Forum (EPF) Annual General Meeting, Brussels, Belgium, April 2024 – attendee
- Outsourcing in Clinical Trials (OCT) Europe, Barcelona, Spain, May 2024 – speaker and panelist
- International Association of Parkinsonism and Related Disorders (IAPRD) World Congress, Lisbon, Portugal, May 2024 – attendee
- Patient Engagement Open Forum (PEOF), Baveno, Italy, May 2024 – attendee
- Patients as Partners Europe, London, UK, May 2024 – attendees
- Congress of the European Academy of Neurology (EAN), Helsinki, Finland, June-July 2024 – attendee
- EUPATI Annual General Meeting, Brussels, Belgium, September 2024 – moderator
- International Congress of Parkinson's Disease and Movement Disorders (MDS), Philadelphia, USA, September-October 2024 – booth
- European Medicines Agency Accelerating Clinical Trials in the EU (ACT-EU) annual meeting, Amsterdam, the Netherlands, October 2024 – moderator
- Online Order and Home Delivery of Medicines (OnHOME) Alliance launch event, Brussels, Belgium, October 2024 – panelist
- First European Non-Pharmacological Intervention Society (NPIS) Forum, Brussels, Belgium, December 2024 – speaker.

Our New Website

Following a major redesign project in the latter half of 2023, our brand-new website went live in March 2024. The new website allows our audience to benefit from:

- much improved navigation, helping people to find the information they need quickly;
- an interactive map for users to easily find Parkinson's events, organisations and initiatives in their country;
- a new and improved home for our online magazine Parkinson's Life, with more regular articles, stories and podcasts;
- an exclusive Members area filled with useful tools and resources for our Member Organisations.

We have continued to add new features and updates to our website over the course of 2024. Results included:

- 300,000 views since the site launched, including users from every European country;
- a 91% engagement rate (which is a 57% increase on the old site);
- hundreds of new pins added to our map, including 50 for World Parkinson's Day covering 25 countries;
- 80 new articles on Parkinson's Life (an 80% increase on our pre-launch numbers), covering stories from 19 European countries (a 73% increase on last year).

Our special thanks go to the following organisations who contributed to the funding of our new website:

- Boston Scientific Foundation Europe
- Bial
- Britannia
- Merz Therapeutics
- Novartis
- Roche
- Servier
- UCB

Our Increased Social Media Presence

In 2024, we wanted to build on our success from 2023, where we grew our social audience by 20%. This is necessary in order to reach more people with Parkinson's who need help and information, to support our Member Organisations and partners in achieving a higher visibility, reach and impact – and to position Parkinson's Europe as a fundamental part of the digital Parkinson's community.

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Throughout the year, people with Parkinson's and our Member Organisations provided moving, authentic and engaging stories for our campaigns and video content. Among others, we collaborated with artist Barbara Salsberg Mathews on her new book, *What Parkinson's Feels Like*: we used social media and other channels to crowdsource contributions to the book, and we launched the book on our website and social media. It has had more than 600 downloads, and helped to raise thousands of pounds in charity donations.

We also worked with our treatment industry partners on important awareness campaigns on topics such as DBS surgery, OFF periods, and Parkinson's care pathways.

Our Enhanced Newsletter

Our 2024 communications strategy has seen us growing our audience and engagement across every channel. We achieved the following results regarding our email marketing:

- We grew our general e-shot audience by 21% to over 4,100.
- We increased our open rate by 5% to almost 49%.
- We established a purpose-driven email campaign schedule, sending regular e-shots highlighting our core campaigns and top content.
- We redesigned our email templates in line with our new branding.
- We increased the visibility of our newsletter to expand our subscriber base – for instance adding a sign-up box on our website homepage, on relevant campaign landing pages, and on our LinkTree profile.

Members Outreach and Support

We have worked hard to support our Member Organisations in 2024, and are pleased to say we've shared a very productive year with all of them.

A number of memorable events have been held by our members this year, and we have been proud to play a part in supporting them in different ways:

- Parkinson Italia's Parkinson's disease – strategies for the future event took place in Rome, in March.
- We introduced our industry partner IQVIA to national Parkinson's organisations in Nordic countries at the start of the year.
- In autumn, we supported events such as Parkinson's UK's 2-day Par-Con and France Parkinson's first Parlons Recherche event, promoting the events across our website, member e-shots and social media platforms.
- We also made a donation to Društvo Trepetlika, helping the Slovenian organisation host the Ping Pong Parkinson World Championship in Laško in October.
- Strategic Director Amelia Hursey was able to host some members for a networking dinner at the International Congress of Parkinson's Disease and Movement Disorders (MDS), Philadelphia, USA, in September.

Parkinson's Europe was pleased to welcome two new member organisations this year:

- PAR.KIN.S.O.N. (Greece)
- the Catalan Parkinson's Association (Spain)

A new benefit of membership introduced in 2024 is an interview on Parkinson's Life, allowing new member organisations to introduce themselves, tell the story of their organisation, and share their work with the wider European Parkinson's community. Examples include our interviews with PAR.KIN.S.O.N., the Catalan Parkinson's Association and Cure4Parkinson in Denmark.

Finally, an exclusive members-only section launched on our new website in the spring. Members can now log in to access advocacy toolkits, exclusive travel discounts and more, and we will be adding some exciting new developments to this area in 2025.

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Collaboration with the Treatment Industry

Parkinson's Europe has a 30-year history of positive and fruitful collaboration with the treatment industry – a key stakeholder in the Parkinson's community and a key player in the development of new treatments – and hopefully a cure – for Parkinson's.

Parkinson's Europe would like to sincerely thank the following treatment industry partners for providing funding and support to our activities in 2024:

- Abbott
- AbbVie
- Bial
- Biogen
- Boston Scientific
- Britannia Pharmaceuticals
- Centogene
- Charco Neurotech
- ConvaTec
- Esteve
- Insightec
- IQVIA
- Lundbeck
- Medtronic
- Merz
- Nordic InfuCare
- Novartis
- Parexel
- Roche
- Servier
- UCB
- Zambon

Working Group on Device-Assisted Therapies

In 2024, the group worked together to develop a knowledge-sharing resource aimed at people with Parkinson's and their families to increase their awareness of DATs and empower them to discuss these therapy options with healthcare professionals. All members of the working group contributed their knowledge, expertise and available materials. An initial draft of this knowledge-sharing resource was developed in 2024, and will be launched in the first half of 2025.

Online Campaign on Deep Brain Stimulation and Surgery

In 2024, we invited the three main DBS industry companies (Abbott, Boston Scientific and Medtronic) to support an online multimedia, multi-language campaign aimed at an honest, comprehensive and clear picture of the main aspects to take into account when considering DBS surgery – demystifying common fears and misconceptions but also objectively considering common challenges and critical aspects, with the goal to empower people with Parkinson's to discuss these topics with healthcare professionals and make more informed treatment choices.

In 2024, as part of the campaign we developed:

- a Parkinson's Life article:
 - published in five languages
 - achieved more than 95,000 views
- a set of social media infographics
 - published in five languages
 - achieved nearly 8 million impressions and nearly 30,000 engagements
- a Parkinson's life podcast episode
 - achieved more than 600 downloads by the end of the year.

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

The campaign assets were published and disseminated via our website, newsletter and social media channels, and supported via paid promotion. Nearly 8 million impressions and a very high engagement rate make this the most successful Parkinson's Europe campaign so far.

The campaign will continue in 2025 with the production of video testimonies, a social media quiz and a webinar.

Online Campaign on Parkinson's OFF Periods

OFF periods are among the most important symptoms of Parkinson's, affecting the majority of people living with the condition and significantly impacting people's wellbeing and social life – as well as those of their family members and caregivers.

In late 2023 and early 2024, we launched an online awareness campaign supported by our industry partner Bial, aimed at raising awareness of the impact of Parkinson's OFF periods, informing people about how to recognise and anticipate them, as well as about available treatment options. As part of this campaign, we developed:

- a Parkinson's Life article
- a set of social media infographics
- a set of video testimonials

The campaign was very successful, with nearly 250,000 impressions and a very high engagement rate. In 2024, we invited our industry partner companies Bial and Esteve to support an extension of the campaign, with the goal of translating the campaign content into several languages and further disseminating it to a broader European audience.

The translated campaign assets were developed in 2024 and will be launched and disseminated in 2025.

Information and Awareness about Disease-Modifying Therapies

In 2024, Parkinson's Europe worked with our industry partners UCB and Novartis around the development of an information and awareness campaign about DMTs. By being involved in several advisory boards and review activities (which involved other important international stakeholders such as Parkinson's UK and the Michael J Fox Foundation), we contributed extensively to the development of a clear and consistent narrative and set of main messages on the

This important information will be translated and disseminated to the Parkinson's community, with the involvement of national Parkinson's organisations, as part of a multi-media awareness campaign in 2025.

Addressing Barriers to Care for People with Advanced Parkinson's – Call to Action

In January 2024, Parkinson's Europe and our industry partner AbbVie co-hosted a roundtable on the topic of care pathways for people with advanced Parkinson's. Expert panelists from different European countries – movement disorder specialists, nurses, researchers, people with Parkinson's and representatives of Parkinson's organisations – gave insights about barriers and best practices around care pathways for advanced Parkinson's, highlighting gaps and common areas for improvement and identifying possible solutions. The main findings of this roundtable were published into a report and an infographic.

Following the success of the roundtable, we have been working with AbbVie and other important stakeholders (the European Federation of Neurological Association, EFNA, and the International Parkinson and Movement Disorder Society European Section, MDS-ES) in the development of a joint call to action aimed at European policymakers – calling for a commitment to improving healthcare services for people with Parkinson's and a pledge to make progress in the following three key areas:

- the recruitment and retention of essential healthcare workforce
- the formalisation of neurodegenerative nurses in healthcare systems
- access to innovation to optimise healthcare resources.

The call to action was launched on 29 November 2024 (World Movement Disorders Day), and endorsed by 11 European Parkinson's organisations. In 2025, we will work on a series of awareness activities to leverage this call to action and call for better healthcare for people with Parkinson's in Europe.

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024**

Financial review

During the year under review there was a increase of £73,170 (2023: decrease of £53,031) on unrestricted funds and decrease of £10,060 (2023: introduced £87,281) on restricted funds.

Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus, the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements. The Charity's reserve policy is to hold reserves only to cover a period of 4 months administration costs. No additional reserves are intended to be held.

Reserves policy

It is the policy of the charity that unrestricted funds which have not been designated for a specific use should be maintained at a level equivalent to 4 month's expenditure. The trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity's current activities while consideration is given to ways in which additional funds may be raised. This level of reserves has been maintained throughout the year.

Structure, governance and management

The charity was established by a charitable trust deed on 25th April 1998 in Belgium and registered as a Charitable Incorporated Organisation in the UK on 19th August 2015.

The trustees have had regard to the Charity Commission's guidance on public benefit.

The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

G Boyle	
J M M Domingos	
P Perez Librero	(Resigned 9 May 2024)
C P Likar	
A Moretti	
T Shaish	(Resigned 26 June 2024)
A S Butler	
B J Magennis	
K Wouters	
J Sinclair	(Appointed 26 June 2024)
E Ildal	(Appointed 26 June 2024)
C Molohan	(Appointed 26 June 2024)
C Bale	(Appointed 26 June 2024)

The following individuals were observer trustees during the period:

C Bale (elected in June 2024)
E Ildal (elected in June 2024)
C Molohan (elected in June 2024)
J Sinclair (elected in June 2024)

The following individuals retired during the period:

P Pérez Librero (retired in April 2024)
T Shaish (retired in June 2024)

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

The trustees' report was approved by the Board of Trustees.



J M M Domingos

Trustee

Date: Thursday 19 June 2025

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF PARKINSON'S EUROPE**

I report to the trustees on my examination of the financial statements of Parkinson's Europe (the charity) for the year ended 31 December 2024.

Responsibilities and basis of report

As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).

Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charity's financial statements carried out under section 145 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales., which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
- 4 the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Louise Hallsworth, FCA

Baxter & Co
Chartered Accountants
Lynwood House, Crofton Road
Orpington
Kent
BR6 8QE

Dated: 20 June 2025

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2024

Current financial year		Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Total 2023 £
	Notes				
Income from:					
Donations and legacies	3	28,866	-	28,866	24,134
Charitable activities	4	470,303	3,832	474,135	553,452
Investments	5	693	-	693	478
Total income		499,862	3,832	503,694	578,064
Expenditure on:					
Charitable activities	6	409,470	14,574	424,044	528,345
Total expenditure		409,470	14,574	424,044	528,345
Net income/(expenditure)		90,392	(10,742)	79,650	49,719
Transfers between funds		(682)	682	-	-
Other recognised gains and losses:					
Other losses	12	(16,540)	-	(16,540)	(15,469)
Net movement in funds	8	73,170	(10,060)	63,110	34,250
Reconciliation of funds:					
Fund balances at 1 January 2024		48,463	87,281	135,744	101,494
Fund balances at 31 December 2024		121,633	77,221	198,854	135,744

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
STATEMENT OF FINANCIAL ACTIVITIES (CONTINUED)
INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2024

Prior financial year as restated		Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
	Notes			
Income from:				
Donations and legacies	3	24,134	-	24,134
Charitable activities	4	455,211	98,241	553,452
Investments	5	478	-	478
Total income		479,823	98,241	578,064
Expenditure on:				
Charitable activities	6	517,385	10,960	528,345
Total expenditure		517,385	10,960	528,345
Net income/(expenditure)		(37,562)	87,281	49,719
Other recognised gains and losses:				
Other losses	12	(15,469)	-	(15,469)
Net movement in funds	8	(53,031)	87,281	34,250
Reconciliation of funds:				
Fund balances at 1 January 2023		101,494	-	101,494
Fund balances at 31 December 2023		48,463	87,281	135,744

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
BALANCE SHEET**

AS AT 31 DECEMBER 2024

		2024		2023 as restated	
	Notes	£	£	£	£
Fixed assets					
Intangible assets	13		77,221		42,339
Current assets					
Debtors	14	2,500		56,726	
Cash at bank and in hand		275,369		221,438	
		277,869		278,164	
Creditors: amounts falling due within one year	15	(156,236)		(184,759)	
Net current assets			121,633		93,405
Total assets less current liabilities			198,854		135,744
The funds of the charity					
Restricted income funds	18		77,221		87,281
Unrestricted funds	19		121,633		48,463
			198,854		135,744


The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2024.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the trustees on ...19 June 2025.



J M M Domingos
Trustee

Company registration number CE004367 (England and Wales)

Digita qui il testo

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies

Charity information

Parkinson Europe (formerly European Parkinson's Disease Association) is a Charitable Incorporated Organisation registered in the UK on 19 August 2015.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's Charity's trust deed, the Companies Act 2006, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies

(Continued)

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

Irrecoverable VAT is charged against the expenditure heading for which it was incurred.

1.6 Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Website	not amortised until completed
---------	-------------------------------

1.7 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.8 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities (if any). During the current and prior year there is no overdraft facility has been used on Parkinson's Europe's bank accounts.

1.9 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price.

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies

(Continued)

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price. Financial liabilities classified as payable within one year are not amortised.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less.

1.10 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.11 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.12 Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Income from donations and legacies

	Unrestricted funds 2024 £	Unrestricted funds 2023 £
Donations and gifts	6,484	3,718
Membership fees	22,382	20,416
	<u>28,866</u>	<u>24,134</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

4 Income from charitable activities

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Charitable activities						
Core income	374,981	-	374,981	298,307	98,241	396,548
Project income	92,860	3,832	96,692	154,146	-	154,146
Other income	2,462	-	2,462	2,758	-	2,758
	<u>470,303</u>	<u>3,832</u>	<u>474,135</u>	<u>455,211</u>	<u>98,241</u>	<u>553,452</u>

5 Income from investments

	Unrestricted funds 2024 £	Unrestricted funds 2023 £
Interest receivable	<u>693</u>	<u>478</u>

6 Expenditure on charitable activities

	Charitable activities 2024 £	Charitable activities 2023 £
Direct costs		as restated
Member organisation and board meetings	-	9,181
Advocacy communication and project development	13,094	76,604
Funded projects	21,146	43,313
Other direct costs	20	7,140
Freelancer costs	57,147	111,258
	<u>91,407</u>	<u>247,496</u>
Share of support and governance costs (see note 7)		
Support	319,706	274,625
Governance	12,931	6,224
	<u>424,044</u>	<u>528,345</u>
Analysis by fund		
Unrestricted funds	409,470	517,385
Restricted funds	14,574	10,960
	<u>424,044</u>	<u>528,345</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

6 Expenditure on charitable activities

(Continued)

Included within share of supports costs are wages and salary costs amounting to £13,791 (2023: £10,536) directly attributable to member organisation, board meetings and advocacy in addition to the £13,798 (2023: £17,582) shown above, therefore the total spend for member organisation and board meetings in 2024 amounts to £27,589 (2023: £28,118).

7 Support costs allocated to activities

	2024	2023
	£	£
Staff costs	305,309	262,481
Technology costs	2,500	3,319
Bad debts	-	192
Bank charges	66	314
Bookkeeping costs	4,266	3,960
Other support costs	4,304	2,685
Travel costs	2,017	560
Insurance	1,244	1,114
Governance costs	12,931	6,224
	<u>332,637</u>	<u>280,849</u>
Analysed between:		
Charitable activities	<u>332,637</u>	<u>280,849</u>

8 Net movement in funds

2024
£

2023
£

The net movement in funds is stated after charging/(crediting):

Fees payable for the independent examination of the charity's financial statements	1,386	1,320
	<u>1,386</u>	<u>1,320</u>

9 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year.

10 Employees

The average monthly number of employees during the year was:

	2024	2023
	Number	Number
Administration	6	6
	<u>6</u>	<u>6</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

10 Employees **(Continued)**

Employment costs	2024	2023
	£	£
Wages and salaries	279,275	242,071
Social security costs	19,764	15,162
Other pension costs	6,270	5,248
	<u>305,309</u>	<u>262,481</u>

Last years employment costs were recharged to specific budget headings within the overall expenditure.

The number of employees whose annual remuneration was more than £60,000 is as follows:

	2024	2023
	Number	Number
£60,000 - £70,0000	<u>1</u>	<u>1</u>

Remuneration of key management personnel

The key management personnel of the charity comprise the Trustees and the key management team as listed on page 1. The total amount of key management personnel benefits (including employer pension contributions and employer national insurance contributions) received by key management personnel for their services to the charity was £126,510 (2023: £139,882).

11 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

12 Other gains and losses

	Unrestricted funds	Unrestricted funds
	2024	2023
	£	£
Gains/(losses) upon:		
Foreign exchange	<u>16,540</u>	<u>15,469</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

13 Intangible fixed assets

	Website £
Cost	
At 1 January 2024	42,339
Additions - separately acquired	34,882
At 31 December 2024	77,221
Amortisation and impairment	
At 1 January 2024 and 31 December 2024	-
Carrying amount	
At 31 December 2024	77,221
At 31 December 2023	42,339

14 Debtors

	2024 £	2023 £
Amounts falling due within one year:		
Trade debtors	100	56,726
Prepayments and accrued income	2,400	-
	2,500	56,726

15 Creditors: amounts falling due within one year

	Notes	2024 £	2023 £
Other taxation and social security		4,842	5,047
Deferred income	16	96,133	113,674
Trade creditors		4,440	27,125
Other creditors		17,501	17,267
Accruals		33,320	21,646
		156,236	184,759

16 Deferred income

	2024 £	2023 £
Other deferred income	96,133	113,674

Deferred income is included in the financial statements as follows:

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

16	Deferred income	(Continued)	
		2024 £	2023 £
	Deferred income is included within:		
	Current liabilities	96,133	113,674
		<u> </u>	<u> </u>
	Movements in the year:		
	Deferred income at 1 January 2024	113,674	145,149
	Released from previous periods	(113,674)	(145,149)
	Resources deferred in the year	96,133	113,674
		<u> </u>	<u> </u>
	Deferred income at 31 December 2024	96,133	113,674
		<u> </u>	<u> </u>

17	Retirement benefit schemes	2024 £	2023 £
	Defined contribution schemes		
	Charge to profit or loss in respect of defined contribution schemes	6,270	5,248
		<u> </u>	<u> </u>

The charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charity in an independently administered fund.

18 Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

	At 1 January 2024 £	Incoming resources £	Resources expended £	Transfers £	At 31 December 2024 £
Website	87,281	-	(10,449)	389	77,221
MDS event	-	3,832	(4,125)	293	-
	<u>87,281</u>	<u>3,832</u>	<u>(14,574)</u>	<u>682</u>	<u>77,221</u>
Previous year:	At 1 January 2023 £	Incoming resources £	Resources expended £	Transfers £	At 31 December 2023 £ as restated
Website	-	98,241	(10,960)	-	87,281
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>

The specific purpose for which the Restricted Funds are to be applied is for the development of the New Website and MDS Event.

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

19 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

	At 1 January 2024	Incoming resources	Resources expended	Transfers	Gains and losses	At 31 December 2024
	£	£	£	£	£	£
General funds	48,463	499,862	(409,470)	(682)	(16,540)	121,633
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>
Previous year:	At 1 January 2023	Incoming resources	Resources expended	Transfers	Gains and losses	At 31 December 2023
	£	£	£	£	£	£
General funds	101,494	479,823	(517,385)	-	(15,469)	48,463
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>

20 Analysis of net assets between funds

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £
At 31 December 2024:			
Intangible fixed assets	-	77,221	77,221
Current assets/(liabilities)	121,633	-	121,633
	<u> </u>	<u> </u>	<u> </u>
	121,633	77,221	198,854
	<u> </u>	<u> </u>	<u> </u>
	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
At 31 December 2023:			
Intangible fixed assets	-	42,339	42,339
Current assets/(liabilities)	48,463	44,942	93,405
	<u> </u>	<u> </u>	<u> </u>
	48,463	87,281	135,744
	<u> </u>	<u> </u>	<u> </u>

21 Related party transactions

There were no disclosable related party transactions during the year (2023 - none), other than those disclosed within the trustees note in note 9.

22 Prior year restatement

The prior year restatement was made to capitalise the Intangible fixed assets of £42,339 for the new website.

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)**

KEY REPORTS AND NOTES IN EURO EQUIVALENT AT THE YEAR END

These pages do not form part of the statutory financial statements

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT (EURO)

FOR THE YEAR ENDED 31 DECEMBER 2024

	Unrestricted funds	Unrestricted funds	Restricted funds	Restricted funds
	2024	2024	2024	2024
	£	€	£	€
Income from:				
Donations and legacies	28,866	34,926	-	-
Charitable activities	470,303	569,030	3,832	4,636
Investment income	<u>693</u>	<u>838</u>	<u>-</u>	<u>-</u>
Total income	<u>499,862</u>	<u>604,794</u>	<u>3,832</u>	<u>4,636</u>
Expenditure on:				
Charitable activities	<u>409,470</u>	<u>495,426</u>	<u>14,574</u>	<u>17,633</u>
Net income / (expenditure)	90,392	109,367	(10,742)	(12,997)
Transfers between funds	(682)	(825)	682	825
Other recognised gains and losses				
Other currency revaluation gains or losses	-	2,713	-	4,886
Other gains / (losses)	<u>(16,540)</u>	<u>(20,012)</u>	<u>-</u>	<u>-</u>
Net movement in funds	73,170	91,243	(10,060)	(7,286)
Fund balances at 1 January 2024	<u>48,436</u>	<u>55,923</u>	<u>87,281</u>	<u>100,717</u>
Fund balances at 31 December 2024	<u>121,633</u>	<u>147,166</u>	<u>77,221</u>	<u>93,431</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT (EURO)

FOR THE YEAR ENDED 31 DECEMBER 2024

<i>Comparative information</i>	Unrestricted funds	Unrestricted funds	Restricted funds	Restricted funds
	2023	2023	2023	2023
	£	€	£	€
Income from:				
Donations and legacies	24,134	27,849	-	-
Charitable activities	455,211	525,284	98,241	113,364
Investment income	<u>478</u>	<u>552</u>	<u>-</u>	<u>-</u>
Total income	<u>479,823</u>	<u>553,685</u>	<u>98,241</u>	<u>113,364</u>
Expenditure on:				
Charitable activities	<u>517,385</u>	<u>597,029</u>	<u>10,960</u>	<u>12,647</u>
Net income / (expenditure)	(37,562)	(43,344)	87,281	100,717
Transfers between funds				
Other recognised gains and losses				
Other currency revaluation gains or losses	-	2,667	-	-
Other gains / (losses)	<u>(15,469)</u>	<u>(17,850)</u>	<u>-</u>	<u>-</u>
Net movement in funds	(53,031)	(58,527)	87,281	100,717
Fund balances at 1 January 2023	<u>101,494</u>	<u>114,450</u>	<u>-</u>	<u>-</u>
Fund balances at 31 December 2023	<u>48,463</u>	<u>55,923</u>	<u>87,281</u>	<u>100,717</u>

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
BALANCE SHEET (EURO)**

AS AT 31 DECEMBER 2024

	2024	2024	2023	2023
	£	€	£	€
Fixed assets				
Intangible assets	77,221	93,431	42,339	48,856
Current assets				
Debtors	2,500	3,025	56,726	65,458
Cash at bank and in hand	<u>275,369</u>	<u>333,175</u>	<u>221,438</u>	<u>255,525</u>
	277,869	336,200	278,164	320,983
Creditors: amounts falling due within one year	<u>(156,236)</u>	<u>(189,033)</u>	<u>(184,759)</u>	<u>(213,200)</u>
Net current assets	<u>121,633</u>	<u>147,166</u>	<u>93,405</u>	<u>107,783</u>
Total assets less current liabilities	<u>198,854</u>	<u>240,598</u>	<u>135,744</u>	<u>156,640</u>
Income funds				
Restricted funds	77,221	93,431	87,281	100,717
Unrestricted funds	<u>121,633</u>	<u>147,166</u>	<u>48,463</u>	<u>55,923</u>
Total funds	<u>198,854</u>	<u>240,598</u>	<u>135,744</u>	<u>156,640</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (EURO)

FOR THE YEAR ENDED 31 DECEMBER 2024

INCOME	Unrestricted funds	Unrestricted funds	Restricted funds	Restricted funds
	2024	2024	2024	2024
	£	€	£	€
Donations and legacies				
Donations and gifts	6,484	7,845	-	-
Membership fees	<u>22,382</u>	<u>27,080</u>	<u>-</u>	<u>-</u>
	<u>24,134</u>	<u>27,849</u>	<u>-</u>	<u>-</u>
Charitable activities				
Core income	374,981	453,698	-	-
Project income	92,860	112,353	3,832	4,636
Other income	<u>2,462</u>	<u>2,979</u>	<u>-</u>	<u>-</u>
	<u>470,303</u>	<u>569,030</u>	<u>3,832</u>	<u>4,636</u>
Investment income				
Interest receivable	<u>693</u>	<u>838</u>	<u>-</u>	<u>-</u>
INCOME	Unrestricted funds	Unrestricted funds	Restricted funds	Restricted funds
Comparative information	2023	2023	2023	2023
	£	€	£	€
Donations and legacies				
Donations and gifts	3,781	4,290	-	-
Membership fees	<u>20,416</u>	<u>23,559</u>	<u>-</u>	<u>-</u>
	<u>24,134</u>	<u>27,849</u>	<u>-</u>	<u>-</u>
Charitable activities				
Core income	298,307	344,227	98,241	113,364
Project income	154,146	177,874	-	-
Other income	<u>2,758</u>	<u>3,183</u>	<u>-</u>	<u>-</u>
	<u>455,211</u>	<u>525,284</u>	<u>98,241</u>	<u>113,364</u>
Investment income				
Interest receivable	<u>478</u>	<u>552</u>	<u>-</u>	<u>-</u>

This page does not form part of the statutory financial statements

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (EURO)

FOR THE YEAR ENDED 31 DECEMBER 2024

EXPENDITURE	Unrestricted funds 2024 £	Unrestricted funds 2024 €	Restricted funds 2024 £	Restricted funds 2024 €
Charitable activities				
Direct costs				
Member organisation and board meetings	-	-	-	-
Advocacy communication and project development	13,094	15,843	-	-
Funded projects	18,785	22,728	2,361	2,857
Other direct costs	20	24	-	-
Freelancer costs	<u>56,319</u>	<u>68,142</u>	<u>828</u>	<u>1,001</u>
	<u>88,218</u>	<u>106,737</u>	<u>3,189</u>	<u>3,858</u>
Support costs				
Staff costs	293,924	355,625	11,385	13,775
Technology costs	2,500	3,025	-	-
Bank charges	66	80	-	-
Bookkeeping costs	4,266	5,162	-	-
Other support costs	4,304	5,208	-	-
Travel costs	2,017	2,440	-	-
Insurance	1,244	1,505	-	-
Governance costs	<u>12,931</u>	<u>15,645</u>	<u>-</u>	<u>-</u>
	<u>321,252</u>	<u>388,690</u>	<u>11,385</u>	<u>13,775</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (EURO)

FOR THE YEAR ENDED 31 DECEMBER 2024

EXPENDITURE	Unrestricted funds	Unrestricted funds	Restricted funds	Restricted funds
<i>Comparative information</i>	2023	2023	2023	2023
	£	€	£	€
Charitable activities				
Direct costs				
Member organisation and board meetings	9,181	10,594	-	-
Advocacy communication and project development	76,604	88,396	42,339	48,856
Funded projects	43,313	49,980	-	-
Other direct costs	7,140	8,239	-	-
Freelancer costs	<u>102,672</u>	<u>118,477</u>	<u>8,586</u>	<u>9,908</u>
	<u>238,910</u>	<u>275,687</u>	<u>50,925</u>	<u>58,764</u>
Support costs				
Staff costs	260,138	300,182	2,343	2,704
Technology costs	3,288	3,794	-	-
Bank charges	314	362	-	-
Bookkeeping costs	2,685	3,098	-	-
Other support costs	2,685	3,098	-	-
Travel costs	560	646	-	-
Insurance	1,114	1,285	-	-
Governance costs	<u>6,224</u>	<u>7,182</u>	<u>-</u>	<u>-</u>
	<u>278,475</u>	<u>321,342</u>	<u>2,374</u>	<u>2,739</u>

Parkinson's Europe

England & Wales - Charity number 1163211

Accounts

Charity registration number 1163211

Company registration number CE004367 (England and Wales)

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

PARKINSON'S EUROPE

(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	G Boyle J M M Domingos P Perez Librero C P Likar A Moretti T Shaish A S Butler B J Magennis K Wouters	(Appointed 27 June 2023) (Appointed 27 June 2023) (Appointed 27 June 2023)
Key Personnel	Rusell Patten Dominic Graham Lisa Wong	Director General Operations Director Finance Manager
Charity number	1163211	
Company number	CE004367	
Registered office	Lynwood House Crofton Road Orpington Kent BR6 8QE	
Independent examiner	Louise Hallsworth, FCA Baxter & Co Chartered Certified Accountants Lynwood House, Crofton Road Orpington Kent BR6 8QE	

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) CONTENTS

	Page
Trustees' report	1 - 7
Independent examiner's report	8
Statement of financial activities	9
Balance sheet	10
Notes to the financial statements	11 - 19

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 31 DECEMBER 2023

The trustees present their annual report and financial statements for the year ended 31 December 2023.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's constitution, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019).

Objectives and activities

The trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

Research: a new workstream

Research Steering Group

To make sure the new Parkinson's Europe [research strategy](#) truly reflects the voice of the Parkinson's community, we created a Research Steering Group (RSG) in Q3 2022. The group represents our key stakeholders (people affected by Parkinson's, healthcare professionals, Parkinson's Europe Member Organisations and the treatment industry), and will focus and deliver on our research offer.

Research Strategy

The RSG's initial work was to guide the creation of the Parkinson's Europe Research Strategy, based on insights gathered from our Member Organisations and treatment industry partners about their patient involvement and engagement activities in the research space. The RSG then helped with the development and translation of the Research Strategy Executive Summary into nine languages.

The Research Strategy was then launched in Q2 2023 with a [new webpage](#) and a social media campaign, which achieved 11,500 impressions and 600 engagements.

Our Research Strategy will ensure all stakeholders have a clear understanding of Parkinson's Europe's aims and ambitions in the research space – and will be the foundation to deliver on our [Strategic Goal 4](#).

For more information about our activities on research, please contact amelia@parkinsonseurope.org.

Parkinson's Europe Engagement Network

Parkinson's Europe recognised the need to reach more people across Europe in a strategic and constructive way, to share calls to action that would help us achieve our current and future strategic activities and support the many significant advancements for the Parkinson's community that are continually taking place in different areas (such as research, advocacy and knowledge sharing).

Having secured funding from CRO company IQVIA in 2023, we developed the technical infrastructure to make the Parkinson's Europe Engagement Network ([PEN](#)) possible. The PEN is an online network designed to connect people affected by Parkinson's with opportunities they can actively take part in that will impact their future. People who sign up to the PEN will benefit by having opportunities they are interested in sent directly to them via email, according to their own interests and preferences.

In the development phase, we involved our stakeholders when discussing how the PEN would function; we then connected with all our volunteers and friends (a mix of organisations and individuals) to support the alpha and beta phases of testing of the network.

The PEN was launched in December 2023, and we have been actively promoting engagement since then. Opportunities shared with the PEN members in the initial weeks had a very high rate of interest and participation – supporting the delivery of our [Strategic Goals 3 and 4](#).

For more information about the PEN, please contact amelia@parkinsonseurope.org.

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Our advocacy activities at the European level

Campaign advocating for a ban of glyphosate

In 2023, the licence for the use of glyphosate – a herbicide associated with a perceived higher risk of developing Parkinson's – ended in the European Union (EU). A renewal process was started by a list of companies and led by the European Commission. To combat this plan, Parkinson's Europe started an advocacy campaign calling for the glyphosate licence *not* to be renewed for another 10 years. Instead, we asked that the licence be extended for only one year, to allow time to carry out further independent scientific research on glyphosate's safety.

Our [campaign](#) started in November 2023, involving a number of our Member Organisations and other Parkinson's organisations, as well as other pan-European organisations (including PAN Europe and EFNA) and important KOLs from the medical and scientific world. Our stakeholders joined a Parkinson's Europe-led pan-European campaign, and were provided information and lobbying materials that we developed such as information sheets, letter templates, social media content and press releases.

We also reached out to our online community via social media, news articles, press releases and social media infographics translated into six languages. The online campaign achieved:

- 31,000 impressions
- 1,800 engagements
- 175 new followers
- 1,100 visits to the Parkinson's Europe campaign webpage.

Although glyphosate was re-approved for 10 years in late November 2023 by the European Commission, we will continue our efforts to lobby against glyphosate and seek to involve more and a broader range of stakeholders. This campaign work supports our [Strategic Goals](#) 2 and 3.

Parkinson's Advocacy Group Forum

The treatment industry is a key stakeholder in the Parkinson's community, and we therefore acknowledge the need to involve industry representatives in our political advocacy work.

In October 2023, we launched the Parkinson's Advocacy Group (PAG) Forum, which brings together representatives of our Member Organisations as well as of our industry partners with the purpose of exploring political advocacy issues on which we could work together to find synergies and achieve win-win results for all parties.

The PAG Forum will be meeting regularly every three months. These meetings deliver great value both to Parkinson's Europe, our members and our industry partners, in support of our [Strategic Goal](#) 3.

For more information about our political advocacy activities, please contact russell@parkinsonseurope.org, fiona@parkinsonseurope.org or adrien@parkinsonseurope.org.

Our global reach, engagement and collaboration

World Parkinson's Day 2023

World Parkinson's Day (WPD) is one of Parkinson's Europe's key focuses, and for 2023 our key campaign objectives were:

1. To support members and the wider Parkinson's community to raise awareness of Parkinson's via their own campaigns and activities
2. To showcase and promote campaigns across the globe on our online map and social media campaign
3. To gain support for World Parkinson's Day to be officially recognised and observed as a global health day.

With our 2023 campaign, we aimed to primarily reach and engage with local, national, regional and international Parkinson's organisations, as well as with global health organisations (such as the World Health Organisation, WHO). In addition, we also targeted individuals affected by Parkinson's, influencers, the academic world and the industry.

We consistently involved and supported our Member Organisations throughout the planning and development of the campaign by:

- producing a [campaign toolkit](#)
- organising a communications workshop
- adding our Members' events to our online WPD map.

PARKINSON'S EUROPE

(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

On an individual level, anyone from the Parkinson's community was able to join our call to raise the profile and increase the recognition of WPD across the world.

We produced a wide array of campaign communication materials (meeting updates, e-shots, social media posts, website updates, [articles](#)) to make sure all our partners and Members were aware of our plans and how to get involved. Our Members and all organisations involved benefited by having a platform to amplify their campaigns, which helped increase awareness of Parkinson's in general – consistently with our [Strategic Goals](#) 2 and 3.

The figures below show the wide reach and engagement of our campaign:

- 90 events recorded from 40 countries
- 1,000+ supported us to make WPD an official world health day
- [What does Parkinson's mean to me?](#) was the most viewed video ever for Parkinson's Europe
- 3,800 engagements on social media
- 355,000 impressions (1,430% increase compared with 2022)
- 350 new followers
- 5,000 visitors to the Parkinson's Europe website
- 34,000 video views
- 340% increase in engagements.

World Parkinson Congress 2023

The World Parkinson Congress (WPC) is the only international Parkinson's congress. The 2023 edition was held in Barcelona, Spain, and it saw a very high participation from the European Parkinson's community – it was therefore a key event for Parkinson's Europe to attend and be actively engaged with.

Parkinson's Europe's key goals from participating in the WPC were:

1. Networking, engagement and increasing brand awareness
4. Scientific, research and working group input
5. Fundraising and engagement with the treatment industry
6. To develop an advocacy plan to shape political thinking and engagement.

We supported our Member Organisations to attend the WPC, providing a €1,000 grant to seven organisations.

Members of the Parkinson's Europe Team, including our Director General, were consistently involved in the WPC Leadership Forum and supporting Working Groups in the years leading up to the WPC, which meant that our organisation helped shape the Congress agenda and priority focus.

By attending the WPC, we achieved a significant level of engagement and interaction with all Parkinson's community stakeholders – which will help us deliver all our four [Strategic Goals](#):

- +350 followers, 169,000 impressions and 7,000 engagements to our social media campaign
- Dozens of individuals completed the 'Connect with us' forms at the Parkinson's Europe booth
- Engagement with 30 new Parkinson's organisations
- 15 meetings with treatment industry companies (pharmaceutical and technology)
- 150+ people attended our social networking event
- 4 poster presentations
- 1 prestigious Robin A Elliott Award for Outstanding Community Service awarded to Parkinson's Europe co-founder Lizzie Graham.

For more information about our global stakeholder engagement activities, please contact fiona@parkinsonseurope.org.

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Online communication: delivering information and boosting Parkinson's awareness

Our new website

The Parkinson's Europe website had not had a major upgrade or restructure in several years, and we discovered it was no longer serving our audience in the best way – making it harder for users to find what they need, and affecting our SEO and traffic potential as a result.

As our website serves the whole Parkinson's community and is a key part of our organisation's brand and offering, we needed to develop a new platform to better meet the needs of our audience, increase our traffic, and help us communicate our core goals and campaigns in a more effective, up-to-date and impactful way.

The new website redevelopment kicked off in the summer of 2023, involving a web design agency, and launched in March 2024. Several of our industry partners sponsored this work and to whom we are most grateful.

Throughout the process, we carried out user surveys with people from the Parkinson's community and key stakeholders to understand what they would like from the new website.

Our website is crucial to our 4 [Strategic Goals](#), and the new website's core features have been designed to support and enhance all of them. The new platform will be easier to navigate, and will include new functionalities such as:

- An exclusive area for our Member Organisations to share resources and information
- An interactive map to help users find relevant events, initiatives, research and information in their country
- Integrating our online magazine Parkinson's Life into the new website.

Growing our social media presence

While enjoying a strong presence across all our core social media channels ([Twitter/X](#), [Facebook](#), [LinkedIn](#) and [Instagram](#)) for years, we wanted to accelerate our growth, engagement and overall impact on social media in 2023 to help us achieve all four [Strategic Goals](#) more widely, and deliver a positive impact by amplifying the voices and messages of people with Parkinson's, our Member Organisations and our industry partners.

Activity took off in early 2023 and is currently ongoing. It has so far seen the active participation of:

- people with Parkinson's, who helped us create several meaningful videos to help our key campaigns for the year
- our Member Organisations, who were involved in social media workshops and in our different awareness campaigns
- our industry partners, as we ran several successful partner campaigns on social media.

All these stakeholders received significant exposure and engagement thanks to Parkinson's Europe sharing their content to a growing and increasingly engaged audience.

Throughout 2023, our social media presence has grown significantly:

- our social media audience grew by 20% to 26,000 followers
- our post engagement grew by 167% to an average of 120 engagements per post (across our four main channels) compared with 2022
- our post impressions grew by 9% in 2023 despite spending significantly less on paid advertisements and posting less frequently than 2022 (according to our new 'quality over quantity' approach)
- for the first time, we consistently got more than 100 likes per post on Instagram, and also got our first two posts with more than 200 likes.

This growth has helped us boost our influence, as we were able to share and interact with key figures in 2023 such as the WHO (on World Parkinson's Day), Paul McCartney (during the WPC), and Jeremy Paxman. It also helped boost our brand visibility by developing a consistent visual brand identity on social media.

For more information about our communication work, please contact laura@parkinsonseurope.org.

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Collaboration with the treatment industry

Parkinson's Europe has a 30-year history of positive and fruitful collaboration with the treatment industry – a key stakeholder in the Parkinson's community and a key player in the development of new treatments – and hopefully a cure – for Parkinson's.

We often engage in important mutually beneficial partnership projects with our industry partners that aim to benefit the wider European Parkinson's community. Below are two examples of successful projects we developed or concluded in 2023.

Parkinson's Europe would like to sincerely thank our treatment industry partners for providing funding and support to our activities in 2023. For more information about our funding partners, please visit [here](#). **For more information about the projects below and our collaboration with the industry, please contact francesco@parkinsonseurope.org.**

Multi-company working group on device-assisted therapies

Device-assisted therapies (DATs) have proven effective in improving the quality of life of people with Parkinson's. Yet, testimonies and evidence increasingly tell us that not all people who may be suitable for these treatments receive them – which results in sub-optimal treatment and reduced quality of life for people with Parkinson's, their families and caregivers.

Understanding this challenge, Parkinson's Europe invited representatives of companies developing infusion pumps for levodopa, infusion pumps for apomorphine and deep brain stimulation devices to join a working group to a) explore common challenges and b) identify possible joint actions to improve people with Parkinson's engagement with – and access to – DATs.

The working group firstly identified, mapped and prioritised specific challenges and pinch points in the pathway from the development of a DAT product to its distribution – pointing out common challenges along the way and identifying those that are considered as a priority and which fall within the work remit of Parkinson's Europe. The group subsequently agreed to develop a knowledge-sharing resource aimed at people with Parkinson's and their families to increase their awareness of DATs and empower them to discuss these therapy options with healthcare professionals. This work will continue in 2024.

This project is successfully bringing together different stakeholders to collaborate and share knowledge and good practices from their existing work areas (consistent with our [Strategic Goal 2](#)). It also aims to develop information resources aimed at people with Parkinson's and their families (consistent with our [Strategic Goal 1](#)).

Survey on awareness of advanced Parkinson's and treatment options

Evidence and testimonies show that a significant number of people with Parkinson's may be at the advanced Parkinson's stage but are not gaining access to, or information about, appropriate available treatment options. Topics such as symptom progression and decline in the effectiveness of oral medication are not always discussed with healthcare professionals – potentially resulting in sub-optimal treatments and reduced quality of life.

In 2021, Parkinson's Europe (in collaboration with industry partner Britannia Pharmaceuticals) launched an online [multi-language survey](#) focused on advanced Parkinson's and awareness about treatment options.

The results showed, among other things, that people with Parkinson's experience variations in effects of oral medications, but lack expert advice. The full results were published in three scientific posters (presented at three international scientific congresses, in 2022 and 2023). In June 2023, a [report](#) aimed at the Parkinson's community was published and disseminated widely, helping to increase the knowledge and awareness (both among people with Parkinson's and healthcare professionals, consistent with our [Strategic Goals 1 and 3](#)) about advanced Parkinson's diagnosis, management and treatment options.

Although this project is now concluded, the results of this survey are being used to inform further work carried out around the topic of advanced Parkinson's and non-oral therapies.

In 2023, Parkinson's Europe secured 20 funding partners. We would like to sincerely thank each and every one of them for providing funding and support to our activities in 2023. For more information about all of Parkinson's Europe's [partners](#), please visit our [partners](#) web page."

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

Financial review

During the year under review there was a decrease of £53,031 (2022: decrease of £245,750) on unrestricted funds and restricted funds introduced of £44,942.

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements. The Association's reserve policy is to hold reserves only to cover a period of 3 to 6 months administration costs. No additional reserves are intended to be held.

It is the policy of the charity that unrestricted funds which have not been designated for a specific use should be maintained at a level equivalent to between three and six month's expenditure. The trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity's current activities while consideration is given to ways in which additional funds may be raised. This level of reserves has been maintained throughout the year.

Structure, governance and management

The charity was established by a charitable trust deed on 25th April 1998 in Belgium and registered as a Charitable Incorporated Organisation in the UK on 19th August 2015.

The trustees have had regard to the Charity Commission's guidance on public benefit.

The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:


G Boyle	
V Clark	(Resigned 27 June 2023)
J M M Domingos	
L Graham	(Resigned 27 June 2023)
D J Lavender MBE	(Resigned 27 June 2023)
P Perez Librero	
C P Likar	
A Moretti	
T Shaish	
A S Butler	(Appointed 27 June 2023)
B J Magennis	(Appointed 27 June 2023)
K Wouters	(Appointed 27 June 2023)

The following individuals were observer trustees during the period:

A Butler (Resigned June 2023)
B Magennis (Resigned June 2023)
B Morandi (Resigned June 2023)
K Wouters (Resigned June 2023)

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

The trustees' report was approved by the Board of Trustees.



J M M Domingos

Trustee

Date: Wednesday 26 June 2024

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF PARKINSON'S EUROPE**

I report to the trustees on my examination of the financial statements of Parkinson's Europe (the charity) for the year ended 31 December 2023.

Responsibilities and basis of report

As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).

Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charity's financial statements carried out under section 145 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of FCA, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
- 4 the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Louise Hallsworth, FCA

Baxter & Co
Chartered Certified Accountants
Lynwood House, Crofton Road
Orpington
Kent
BR6 8QE

Dated: 26 June 2024....

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2023

	Notes	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £
Income from:					
Donations and legacies	3	24,134	-	24,134	22,472
Charitable activities	4	455,211	98,241	553,452	301,867
Investments	5	478	-	478	25
Total income		479,823	98,241	578,064	324,364
Charitable activities	6	517,385	53,299	570,684	575,003
Net income/(expenditure)		(37,562)	44,942	7,380	(250,639)
Other recognised gains and losses:					
Other gains/(losses)	12	(15,469)	-	(15,469)	4,889
Net movement in funds		(53,031)	44,942	(8,089)	(245,750)
Reconciliation of funds:					
Fund balances at 1 January 2023		101,494	-	101,494	347,244
Fund balances at 31 December 2023		48,463	44,942	93,405	101,494

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
BALANCE SHEET
AS AT 31 DECEMBER 2023

	Notes	2023 £	£	2022 £	£
Current assets					
Debtors	13	56,726		60,431	
Cash at bank and in hand		221,438		237,147	
		<u>278,164</u>		<u>297,578</u>	
Creditors: amounts falling due within one year	14	184,759		196,084	
		<u>184,759</u>		<u>196,084</u>	
Net current assets			93,405		101,494
			<u>93,405</u>		<u>101,494</u>
The funds of the charity					
Restricted income funds	16		44,942		-
Unrestricted funds			48,463		101,494
			<u>93,405</u>		<u>101,494</u>
			<u>93,405</u>		<u>101,494</u>


The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2023.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the trustees on Wednesday 26 June 2024


J M M Domingos
Trustee

Company registration number CE004367 (England and Wales)

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

Charity information

Parkinson Europe (formerly European Parkinson's Disease Association) is a Charitable Incorporated Organisation registered in the UK on 19 August 2015.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's Charity's trust deed, the Companies Act 2006, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

(Continued)

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

Irrecoverable VAT is charged against the expenditure heading for which it was incurred.

1.6 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities (if any). During the current and prior year there is no overdraft facility has been used on Parkinson's Europe's bank accounts.

1.7 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies **(Continued)**

1.8 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.10 Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Income from donations and legacies

	Unrestricted funds 2023 £	Unrestricted funds 2022 £
Donations and gifts	3,718	3,581
Membership fees	20,416	18,891
	<u>24,134</u>	<u>22,472</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

4 Income from charitable activities

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
Core income	298,307	98,241	396,548	246,968	-	246,968
Project income	154,146	-	154,146	134,173	-	134,173
Other income	2,758	-	2,758	(79,274)	-	(79,274)
	<u>455,211</u>	<u>98,241</u>	<u>553,452</u>	<u>301,867</u>	<u>-</u>	<u>301,867</u>

5 Income from investments

	Unrestricted funds 2023 £	Unrestricted funds 2022 £
Interest receivable	<u>478</u>	<u>25</u>

6 Expenditure on charitable activities

	Charitable activities 2023 £	Charitable activities 2022 £
Direct costs		
Member organisation and board meetings	9,181	15,636
Advocacy communication and project development	118,943	89,700
Funded projects	43,313	59,445
Other direct costs	7,140	407
Freelancer costs	111,258	180,742
	<u>289,835</u>	<u>345,930</u>
Share of support and governance costs (see note 7)		
Support	274,625	226,503
Governance	6,224	2,570
	<u>570,684</u>	<u>575,003</u>
Analysis by fund		
Unrestricted funds	517,385	575,003
Restricted funds	53,299	-
	<u>570,684</u>	<u>575,003</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

6 Expenditure on charitable activities

(Continued)

Included within share of supports costs are wages and salary costs amounting to £10,536 (2022: £13,654) directly attributable to member organisation, board meetings and advocacy in addition to the £17,582 (2022: £15,636) shown above, therefore the total spend for member organisation and board meetings in 2023 amounts to £28,118 (2022: £29,260).

7 Support costs allocated to activities

	2023	2022
	£	£
Staff costs	262,481	210,412
Technology costs	3,319	2,944
Bad debts	192	241
Bank charges	314	256
Bookkeeping costs	3,960	3,886
Other support costs	2,685	3,831
Travel costs	560	3,857
Insurance	1,114	1,076
Governance costs	6,224	2,570
	<u>280,849</u>	<u>229,073</u>
Analysed between:		
Charitable activities	<u>280,849</u>	<u>229,073</u>

8 Trustees

During the year, payments totalling £8,239 (2022: £30,877) were reimbursed or paid directly to two Trustees as follows;

Ms M E Graham (resigned 27/06/2023) received fees totalling £8,239 (2022: £30,195) in connection with her role as strategic advisor. The payments have been made in accordance with the charity's constitution and approved by the other trustees. A balance of £nil (2022: £2,634) is included within trade creditors as at the year end.

Ms T Shaish received a reimbursement of expenses in relation to a Charity Art project totalling £nil (2022: £682). The payments have been made in accordance with the charity's constitution and approved by the other trustees. No balance was outstanding at the year end.

9 Employees

The average monthly number of employees during the year was:

	2023	2022
	Number	Number
Administration	<u>6</u>	<u>6</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

9 Employees (Continued)

Employment costs	2023	2022
	£	£
Wages and salaries	242,071	195,857
Social security costs	15,162	11,912
Other pension costs	5,248	2,643
	<u>262,481</u>	<u>210,412</u>

Last years employment costs were recharged to specific budget headings within the overall expenditure.

The number of employees whose annual remuneration was more than £60,000 is as follows:

	2023	2022
	Number	Number
£60,000 - £70,0000	<u>1</u>	<u>1</u>

10 Key management personnel

The key management personnel of the charity comprise the Trustees and the key management team as listed on page 1. The total amount of key management personnel benefits (including employer pension contributions and employer national insurance contributions) received by key management personnel for their services to the charity was £139,882 (2022: £179,533).

11 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

12 Other gains and losses

	Unrestricted funds	Unrestricted funds
	2023	2022
	£	£
Gains/(losses) upon:		
Foreign exchange	<u>15,469</u>	<u>(4,889)</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

13 Debtors

	2023	2022
	£	£
Amounts falling due within one year:		
Trade debtors	56,726	58,392
Prepayments and accrued income	-	2,039
	<u>56,726</u>	<u>60,431</u>

14 Creditors: amounts falling due within one year

	2023	2022
	£	£
Other taxation and social security	5,047	8,478
Deferred income	113,674	145,149
Trade creditors	27,125	20,013
Other creditors	17,267	16,924
Accruals	21,646	5,520
	<u>184,759</u>	<u>196,084</u>

15 Deferred income

	2023	2022
	£	£
Other deferred income	<u>113,674</u>	<u>145,149</u>

Deferred income is included in the financial statements as follows:

	2023	2022
	£	£
Deferred income is included within:		
Current liabilities	<u>113,674</u>	<u>145,149</u>
Movements in the year:		
Deferred income at 1 January 2023	145,149	134,194
Released from previous periods	(145,149)	(134,194)
Resources deferred in the year	<u>113,674</u>	<u>145,149</u>
Deferred income at 31 December 2023	<u>113,674</u>	<u>145,149</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

16 Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

	At 1 January 2023	Incoming resources	Resources expended	At 31 December 2023
	£	£	£	£
Website	-	98,241	(53,299)	44,942

The specific purpose for which the Restricted Funds are to be applied is for the development of the New Website.

17 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

	At 1 January 2023	Incoming resources	Resources expended	Gains and losses	At 31 December 2023
	£	£	£	£	£
General funds	101,494	479,823	(517,385)	(15,469)	48,463

Previous year:	At 1 January 2022	Incoming resources	Resources expended	Gains and losses	At 31 December 2022
	£	£	£	£	£
General funds	347,244	324,364	(575,003)	4,889	101,494

18 Analysis of net assets between funds

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Fund balances at 31 December 2023 are represented by:			
Current assets/(liabilities)	48,463	44,942	93,405
	48,463	44,942	93,405

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

18 Analysis of net assets between funds

(Continued)

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
Fund balances at 31 December 2022 are represented by:			
Current assets/(liabilities)	101,494	-	101,494
	<u>101,494</u>	<u>-</u>	<u>101,494</u>

19 Related party transactions

There were no disclosable related party transactions during the year (2022 - none), other than those disclosed within the trustees note in note 8.

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)**

KEY REPORTS AND NOTES IN EURO EQUIVALENT AT THE YEAR END

These pages do not form part of the statutory financial statements

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT (EURO)

FOR THE YEAR ENDED 31 DECEMBER 2023

	Unrestricted funds	Unrestricted funds	Restricted funds	Restricted funds	Unrestricted funds	Unrestricted funds
	2023	2023	2023	2023	2022	2022
	£	€	£	€	£	€
Income from:						
Donations and legacies	24,134	27,849	-	-	22,472	25,341
Charitable activities	455,211	525,284	98,241	113,364	301,867	340,400
Investment income	<u>478</u>	<u>552</u>	<u>-</u>	<u>-</u>	<u>25</u>	<u>28</u>
Total income	<u>479,823</u>	<u>553,685</u>	<u>98,241</u>	<u>113,364</u>	<u>324,364</u>	<u>365,769</u>
Expenditure on:						
Charitable activities	<u>517,385</u>	<u>597,029</u>	<u>53,299</u>	<u>61,504</u>	<u>575,003</u>	<u>648,402</u>
Net income / (expenditure)	(37,562)	(43,344)	44,924	51,860	(250,639)	(282,633)
Other recognised gains and losses						
Other currency revaluation gains or losses	-	2,667	-	-	-	(21,893)
Other gains / (losses)	<u>(15,469)</u>	<u>(17,850)</u>	<u>-</u>	<u>-</u>	<u>4,889</u>	<u>5,513</u>
Net movement in funds	(53,031)	(58,527)	44,942	51,860	(245,750)	(299,013)
Fund balances at 1 January 2023	<u>101,494</u>	<u>114,450</u>	<u>-</u>	<u>-</u>	<u>347,244</u>	<u>413,463</u>
Fund balances at 31 December 2023	<u>48,463</u>	<u>55,923</u>	<u>44,942</u>	<u>51,860</u>	<u>101,494</u>	<u>114,450</u>

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
BALANCE SHEET (EURO)**

AS AT 31 DECEMBER 2023

	2023	2023	2022	2022
	£	€	£	€
Current assets				
Debtors	56,726	65,458	60,431	68,145
Cash at bank and in hand	<u>221,438</u>	<u>255,525</u>	<u>237,147</u>	<u>267,419</u>
	278,438	320,983	297,578	335,564
Creditors: amounts falling due within one year	<u>(184,759)</u>	<u>(213,200)</u>	<u>(196,084)</u>	<u>(221,114)</u>
Net current assets	<u>93,405</u>	<u>107,783</u>	<u>101,494</u>	<u>114,450</u>
Income funds				
Restricted funds	44,942	51,860	-	-
Unrestricted funds	<u>48,463</u>	<u>55,923</u>	<u>101,494</u>	<u>114,450</u>
Total funds	<u>93,405</u>	<u>107,783</u>	<u>101,494</u>	<u>114,450</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (EURO)

FOR THE YEAR ENDED 31 DECEMBER 2023

INCOME	Unrestricted funds	Unrestricted funds	Restricted funds	Restricted funds	Unrestricted funds	Unrestricted funds
	2023	2023	2023	2023	2022	2022
	£	€	£	€	£	€
Donations and legacies						
Donations and gifts	3,781	4,290	-	-	3,581	4,038
Membership fees	<u>20,416</u>	<u>23,559</u>	<u>-</u>	<u>-</u>	<u>18,891</u>	<u>21,303</u>
	<u>24,134</u>	<u>27,849</u>	<u>-</u>	<u>-</u>	<u>22,472</u>	<u>25,341</u>
Charitable activities						
Core income	298,307	344,227	98,241	113,364	246,968	278,493
Project income	154,146	177,874	-	-	134,173	151,300
Other income	<u>2,758</u>	<u>3,183</u>	<u>-</u>	<u>-</u>	<u>(79,274)</u>	<u>(89,393)</u>
	<u>455,211</u>	<u>525,284</u>	<u>98,241</u>	<u>113,364</u>	<u>301,867</u>	<u>340,400</u>
Investment income						
Interest receivable	<u>478</u>	<u>552</u>	<u>-</u>	<u>-</u>	<u>25</u>	<u>28</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (EURO)

FOR THE YEAR ENDED 31 DECEMBER 2023

EXPENDITURE	Unrestricted funds	Unrestricted funds	Restricted funds	Restricted funds	Unrestricted funds	Unrestricted funds
	2023	2023	2023	2023	2022	2022
	£	€	£	€	£	€
Charitable activities						
Direct costs						
Member organisation and board meetings	9,181	10,594	-	-	15,636	17,632
Advocacy communication and project development	76,604	88,396	42,339	48,856	89,700	101,150
Funded projects	43,313	49,980	-	-	59,445	67,033
Other direct costs	7,140	8,239	-	-	407	459
Freelancer costs	<u>102,672</u>	<u>118,477</u>	<u>8,586</u>	<u>9,908</u>	<u>180,742</u>	<u>203,814</u>
	<u>238,910</u>	<u>275,687</u>	<u>50,925</u>	<u>58,764</u>	<u>345,930</u>	<u>390,088</u>
Support costs						
Staff costs	260,138	300,182	2,343	2,704	210,412	237,271
Technology costs	3,288	3,794	31	36	2,944	3,320
Bad debts	192	222	-	-	241	272
Bank charges	314	362	-	-	256	289
Bookkeeping costs	3,960	4,570	-	-	3,886	4,382
Other support costs	2,685	3,098	-	-	3,831	4,320
Travel costs	560	646	-	-	3,857	4,349
Insurance	1,114	1,285	-	-	1,076	1,213
Governance costs	<u>6,224</u>	<u>7,182</u>	<u>-</u>	<u>-</u>	<u>2,570</u>	<u>2,898</u>
	<u>278,475</u>	<u>321,342</u>	<u>2,374</u>	<u>2,739</u>	<u>229,073</u>	<u>258,314</u>

Parkinson's Europe

England & Wales - Charity number 1163211

Accounts

Charity registration number 1163211

Company registration number CE004367 (England and Wales)

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
LEGAL AND ADMINISTRATIVE INFORMATION**

Trustees

G Boyle
V Clark
J M M Domingos
L Graham
D J Lavender MBE
P Perez Librero
C P Likar
A Moretti
T Shaish

Charity number

1163211

Company number

CE004367

Registered office

Lynwood House
Crofton Road
Orpington
Kent
BR6 8QE

Key Personnel

Russell Patten - Director General
Dominic Graham - Operations Director
Lisa Wong - Finance Manager

Independent examiner

Louise Hallsworth, FCA
Baxter & Co
Chartered Certified Accountants
Lynwood House, Crofton Road
Orpington
Kent
BR6 8QE

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) CONTENTS

	Page
Trustees' report	1 - 4
Independent examiner's report	5
Statement of financial activities	6
Balance sheet	7
Notes to the financial statements	8 - 15

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 31 DECEMBER 2022

The trustees present their annual report and financial statements for the year ended 31 December 2022.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's constitution, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019).

Objectives and activities

The objectives are to promote and protect the physical and mental health of those suffering from Parkinson's disease. In particular but not limited to the following: 1) to challenge existing mind-sets, shift attitudes and remove the hurdles that prevent people with Parkinson's from receiving early and appropriate treatment and individualised care; 2) to increase public and political awareness of Parkinson's and; 3) to help reduce stigma and remove discrimination against people with Parkinson's.

The trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

Achievements and performance

Name change

In 2022, the year of our 30th anniversary, we changed our name from the European Parkinson's Disease Association (EPDA) to **Parkinson's Europe**.

Manifesto

We developed a **Parkinson's Manifesto for Europe** – using the views of more than 900 people from 39 different countries, including people with Parkinson's, caregivers, partners, family members and healthcare professionals, via a European survey and multilingual social media campaign. Summarising 30 wishes of the Parkinson's community, the Manifesto is divided into five key areas: awareness, training, diagnosis and treatment, wellbeing and research. It was launched in October and is available in nine languages, with further translations planned.

It has been endorsed by key Parkinson's opinion leaders such as Dutch neurologist Professor Bas Bloem as well as industry companies and the European Commission.

In 2023, Parkinson's Europe will identify the gaps, challenges and areas of good practice relating to each of the key areas outlined in the manifesto.

Updated strategy

Our amended Vision, Mission and [Strategic Goals](#) were approved by the Parkinson's Europe General Assembly on 29 June 2022, following a thorough review of our six-year plan:

- **Our vision:** That people with Parkinson's and their families have access to the highest standards of treatment, support and care they need to live a full and comfortable life.
- **Our mission:** To work and campaign with people with Parkinson's, their caregivers, families and supporters across Europe to ensure their voices are heard and listened to. We will do this by advocating, raising awareness and working with other global Parkinson's organisations to provide current information, share good practices, and highlight research that will benefit the whole Parkinson's community.

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Research

Research is a new workstream for Parkinson's Europe, which began in January with the recruitment of a Research Manager, Amelia Hursey. Amelia spent 2022 creating our first ever research strategy and Research Steering Group (RSG), which has 11 members from all of our key stakeholder groups. Next year (2023) will see Parkinson's Europe work closely with the RSG and begin implementing our new strategy.

Advocacy

Parkinson's Europe, supported by its Political Advocacy Group (PAG – a working group including members of the Parkinson's Europe Board and representatives from our Member Organisations, who meet regularly to agree on actions regarding the Parkinson's Europe political advocacy strategy), focused on five ongoing campaigns at EU level in 2022: pesticides and Parkinson's; the EU action on non-communicable diseases; the revision of the EU pharmaceutical legislation; educating and influencing EU decision makers on the urgent need to do more about Parkinson's; and ensuring that the EU's future initiative on neurological diseases focuses on Parkinson's.

Parkinson's Europe continued to work with the European Federation of Neurological Associations (EFNA), which has supported the World Health Organisation (WHO) on its Technical Report on Parkinson's, and has created momentum at EU level to directly tackle Parkinson's.

2023 World Parkinson Congress (WPC)

Ahead of this event, which is being held in Barcelona in July 2023, we forged closer relations with its organisers, the World Parkinson Coalition. Parkinson's Europe's Director General, Russell Patten, was appointed as co-chair of the 2023 WPC Leadership Forum.

The 2023 WPC will see the launch of a Political Manifesto – developed by the WPC Leadership Forum thanks to Russell's lead – which will call on all political leaders to tackle Parkinson's head on.

In addition, Parkinson's Europe has been an active partner in four themed initiatives ahead of the WPC. These are: WPC Anti-Stigma Working Group; Young-onset Parkinson's (YOPD) Working Group; WPC Clinical Trials Working Group; WPC Technology Working Group.

The Innovation Lab – an immersion into Parkinson's creativity

In July 2022, Parkinson's Europe held a two-day **Innovation Lab** at the Market Hall in Devonport, Plymouth – a new centre for immersive technology with a state of the art, "first in Europe" immersive dome.

The [Innovation Lab](#) brought together artists with Parkinson's, neurologists and technologists to explore the potential of immersive digital technologies to communicate, develop and enhance the 'creative burst' experienced by people with Parkinson's – with the ultimate aim of creating an immersive experience that would act as a tool to raise awareness, inspire and encourage exploration of Parkinson's creativity.

Planned next steps (subject to available funding) include: a second Innovation Lab to explore immersive technologies with key stakeholders; multidisciplinary events and co-created activities at the World Parkinson Congress 2023; the development of an online repository of initiatives, research and artists; and a toolkit including case studies and ideas.

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

International congresses

Parkinson's Europe Team and Board members attended a number of high-profile international congresses and conferences, raising the profile of Parkinson's Europe and awareness of Parkinson's research, symptoms, treatment and management.

Key highlights include Team and Board members who were chairs and speakers at the International Association of Parkinsonism and Related Disorders (IAPRD) Congress, the European Academy of Neurology (EAN) Congress, and Clinical Trials Europe.

Governance

Parkinson's Europe recruited four new Board observers in 2022, all of whom hope to be elected as full Board members by the Parkinson's Europe General Assembly in June 2023. They are: Andy Butler (UK), of support group [Parkinson's People](#); Brian Magennis (Ireland), Parkinson's nurse specialist; Barbara Morandi (Italy), collaborator of the [Comitato Italiano Associazioni Parkinson](#); Karl Wouters (Belgium), of [Vlaamse Parkinson Liga](#).

Digital communication

In 2022, Parkinson's Europe contracted a new Social Media Consultant and consolidated its presence on different social media platforms – with a view to develop an enhanced social media strategy for 2023.

The readership of our online magazine Parkinson's Life has continued to grow, with more than 180,000 readers from 230 countries.

Membership

One new Member Organisation, [Parkinson Youngster](#) (Germany), was approved by the General Assembly in November.

Grants

Three [projects](#) which received a Parkinson's Europe grant in 2021 were completed by our Member Organisations in:

- Malta – Malta Parkinson's developed a specialised Parkinson's training programme for healthcare professionals;
- Portugal – Associação Portuguesa de Doentes de Parkinson (APDPk) developed a post-COVID exercise and socialising programme for people with Parkinson's, based on table tennis;
- Slovenia – Društvo Trepetlika created a prep school for people newly diagnosed with Parkinson's, their caregivers and relatives.

Our 2022-23 Parkinson's Europe grants will be focused on helping representatives of our Member Organisations attend the World Parkinson Congress (WPC) in July 2023.

Funding partnerships

In 2022, Parkinson's Europe secured 16 funding partners, including Diamond partners AbbVie, Boston Scientific, Britannia Pharmaceuticals and Merz Therapeutics.

Co-created projects included: reviewing and developing the [MY PD-CARE](#) symptoms monitoring tool (AbbVie); disseminating the results of the 2021 [survey](#) on advanced Parkinson's awareness and information (Britannia Pharmaceuticals); disseminating the results of our 2020 [survey](#) on sialorrhea in Parkinson's (Merz); and supporting the [trial](#) of a digital app for music therapy (Air Liquide). Visit our [partners](#) web page for more information.

Parkinson's Europe would like to sincerely thank our treatment industry partners for providing funding and support to our activities in 2022. For more information about all of Parkinson's Europe's partners, please visit our [partners](#) web page.

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022**

Financial review

During the year under review there was a decrease of £245,750 (2021: increase of £41,487) on unrestricted funds.

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements. The Association's reserve policy is to hold reserves only to cover a period of 6 months administration costs. No additional reserves are intended to be held.

It is the policy of the charity that unrestricted funds which have not been designated for a specific use should be maintained at a level equivalent to between three and six month's expenditure. The trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity's current activities while consideration is given to ways in which additional funds may be raised. This level of reserves has been maintained throughout the year.

Structure, governance and management

The charity was established by a charitable trust deed on 25th April 1998 in Belgium and registered as a Charitable Incorporated Organisation in the UK on 19th August 2015.

The trustees have had regard to the Charity Commission's guidance on public benefit.


The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

G Boyle
V Clark
J M M Domingos
L Graham
D J Lavender MBE
P Perez Librero
C P Likar
A Moretti
T Shaish

The following individuals were observer trustees during the period:

A Butler
B Magennis
B Morandi
K Wouters

The trustees' report was approved by the Board of Trustees.



V Clark

Trustee

Date: 10 May 2023

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF PARKINSON'S EUROPE**

I report to the trustees on my examination of the financial statements of Parkinson's Europe (the charity) for the year ended 31 December 2022.

Responsibilities and basis of report

As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).

Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charity's financial statements carried out under section 145 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.


Independent examiner's statement

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of , which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
- 4 the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Louise Hallsworth, FCA

Baxter & Co
Chartered Certified Accountants
Lynwood House, Crofton Road
Orpington
Kent
BR6 8QE

Dated: 29 June 2023
.....

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 31 DECEMBER 2022

	Notes	Unrestricted funds 2022 £	Unrestricted funds 2021 £ as restated
<u>Income from:</u>			
Donations and legacies	3	22,472	31,230
Charitable activities	4	301,867	574,740
Investment income	5	25	8
		<u>324,364</u>	<u>605,978</u>
<u>Expenditure on:</u>			
Charitable activities	6	575,003	541,066
		<u>575,003</u>	<u>541,066</u>
Net (outgoing)/incoming resources		(250,639)	64,912
Other recognised gains and losses			
Other gains or losses	11	4,889	(23,425)
		<u>4,889</u>	<u>(23,425)</u>
Net movement in funds		(245,750)	41,487
Fund balances at 1 January 2022		347,244	305,757
		<u>347,244</u>	<u>305,757</u>
Fund balances at 31 December 2022		<u>101,494</u>	<u>347,244</u>

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
BALANCE SHEET
AS AT 31 DECEMBER 2022

		2022		2021	
	Notes	£	£	as restated	£
Current assets					
Debtors	12	60,431		157,862	
Cash at bank and in hand		237,147		439,558	
		<u>297,578</u>		<u>597,420</u>	
Creditors: amounts falling due within one year	13	(196,084)		(250,176)	
Net current assets			101,494		347,244
Income funds					
Unrestricted funds			101,494		347,244
			<u>101,494</u>		<u>347,244</u>


The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2022.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Trustees on 10 May 2023



V Clark
Trustee

Company registration number CE004367

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022**

1 Accounting policies

Charity information

Parkinson Europe (formerly European Parkinson's Disease Association) is a Charitable Incorporated Organisation registered in the UK on 19 August 2015.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's Charity's trust deed, the Companies Act 2006, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022**

1 Accounting policies

(Continued)

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

Irrecoverable VAT is charged against the expenditure heading for which it was incurred.

1.6 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities (if any). During the current and prior year there is no overdraft facility has been used on Parkinson's Europe's bank accounts.

1.7 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

1 Accounting policies

(Continued)

1.8 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.10 Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Donations and legacies

	Unrestricted funds	Unrestricted funds
	2022	2021
	£	£
Donations and gifts	3,581	6,174
Membership fees	18,891	25,056
	<u> </u>	<u> </u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

4 Charitable activities

	2022	2021
	£	£
		as restated
Core income	246,968	329,878
Project income	134,173	77,959
Other income	(79,274)	166,903
	<u>301,867</u>	<u>574,740</u>

Other income for 2022 includes the repayment of the TreatER grant of £79,274.

5 Investment income

	Unrestricted funds	Unrestricted funds
	2022	2021
	£	£
Interest receivable	<u>25</u>	<u>8</u>

6 Charitable activities

	2022	2021
	£	£
		as restated
Member organisation and board meetings	15,636	39,480
Advocacy communication and project development	89,700	132,352
Funded projects	59,445	140,225
Other direct costs	407	103,368
Freelancer costs	180,742	-
	<u>345,930</u>	<u>415,425</u>
Share of support costs (see note 7)	226,503	116,158
Share of governance costs (see note 7)	2,570	9,483
	<u>575,003</u>	<u>541,066</u>

Included within share of supports costs are wages and salary costs amounting to £13,624 directly attributable to member organisation and board meetings in addition to the £15,636 shown above, therefore the total spend for member organisation and board meetings in 2022 amounts to £29,260 (2021 - £39,480).

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

7 Support costs

	Support costs	Governance costs	2022	Support costs	Governance costs	2021
	£	£	£	£	£	£
						as restated
Staff costs	210,412	-	210,412	22,502	-	22,502
Technology costs	2,944	-	2,944	-	-	-
Fundraising	-	-	-	3,891	-	3,891
Bad debts	241	-	241	540	-	540
Bank charges	256	-	256	374	-	374
Financial administration	-	-	-	22,381	-	22,381
Bookkeeping costs	3,886	-	3,886	11,425	-	11,425
Consultancy fees	-	-	-	7,200	-	7,200
Other support costs	3,831	-	3,831	47,845	-	47,845
Travel costs	3,857	-	3,857	-	-	-
Insurance	1,076	-	1,076	-	-	-
Accountancy	-	1,370	1,370	-	7,483	7,483
Governance costs	-	1,200	1,200	-	2,000	2,000
	<u>226,503</u>	<u>2,570</u>	<u>229,073</u>	<u>116,158</u>	<u>9,483</u>	<u>125,641</u>
Analysed between						
Charitable activities	<u>226,503</u>	<u>2,570</u>	<u>229,073</u>	<u>116,158</u>	<u>9,483</u>	<u>125,641</u>

Governance costs includes payments to the accountants of £1,200 (2021- £2,000- prior accountants) for independent examination fees.

8 Trustees

During the year, payments totalling £30,877 were reimbursed or paid directly to two Trustees as follows;

Ms M E Graham received fees totalling £30,195 (2021: £26,008) in connection with her role as strategic advisor. The payments have been made in accordance with the charity's constitution and approved by the other trustees. A balance of £2,634 is included within trade creditors as at the year end.

Ms T Shaish received a reimbursement of expenses in relation to a Charity Art project totalling £682 (2021: £nil). The payments have been made in accordance with the charity's constitution and approved by the other trustees. No balance was outstanding at the year end.

9 Employees

The average monthly number of employees during the year was:

	2022 Number	2021 Number
Administration	<u>6</u>	<u>4</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

9 Employees		(Continued)	
Employment costs	2022	2021	
	£	£	
Wages and salaries	195,857	22,502	
Social security costs	11,912	-	
Other pension costs	2,643	-	
	<u>210,412</u>	<u>22,502</u>	

Last years employment costs were recharged to specific budget headings within the overall expenditure.

The number of employees whose annual remuneration was more than £60,000 is as follows:

	2022	2021
	Number	Number
£60,000 - £70,0000	<u>1</u>	<u>1</u>

10 Key management personnel

The key management personnel of the charity comprise the Trustees and the key management team as listed on page 1. The total amount of key management personnel benefits (including employer pension contributions and employer national insurance contributions) received by key management personnel for their services to the charity was £179,533.

11 Other gains or losses

	Unrestricted funds	Unrestricted funds
	2022	2021
	£	£
Foreign exchange gains	<u>(4,889)</u>	<u>23,425</u>

12 Debtors

Amounts falling due within one year:	2022	2021
	£	£
Trade debtors	58,392	150,017
Prepayments and accrued income	2,039	7,845
	<u>60,431</u>	<u>157,862</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

13 Creditors: amounts falling due within one year

	Notes	2022 £	2021 £
Other taxation and social security		8,478	2,059
Deferred income	14	145,149	134,194
Trade creditors		20,013	78,336
Other creditors		16,924	16,082
Accruals and deferred income		5,520	19,505
		<u>196,084</u>	<u>250,176</u>

14 Deferred income

	2022 £	2021 £
Other deferred income	145,149	134,194
	<u>145,149</u>	<u>134,194</u>

Deferred income is included in the financial statements as follows:

	2022 £	2021 £
Deferred income is included within:		
Current liabilities	145,149	134,194
	<u>145,149</u>	<u>134,194</u>
Movements in the year:		
Deferred income at 1 January 2022	134,194	166,854
Released from previous periods	(134,194)	(166,854)
Resources deferred in the year	145,149	134,194
	<u>145,149</u>	<u>134,194</u>
Deferred income at 31 December 2022	145,149	134,194
	<u>145,149</u>	<u>134,194</u>

15 Analysis of net assets between funds

	Unrestricted funds 2022 £	Unrestricted funds 2021 £ as restated
Fund balances at 31 December 2022 are represented by:		
Current assets/(liabilities)	101,494	347,244
	<u>101,494</u>	<u>347,244</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

16 Related party transactions

There were no disclosable related party transactions during the year (2021 - none), other than those disclosed within the trustees note in note 8.

17 Prior year restatement

The 2021 comparatives have been restated to reflect that there are no legal restrictions on the funding received and balances held by the Charity relate to unrestricted funds. Additionally some costs this year have been further analysed to reflect transactions in the current year.

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)**

KEY REPORTS AND NOTES IN EURO EQUIVALENT AT THE YEAR END

These pages do not form part of the statutory financial statements

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT (EURO)

FOR THE YEAR ENDED 31 DECEMBER 2022

	Unrestricted funds	Unrestricted funds	Unrestricted funds	Unrestricted funds
	2022	2022	2021	2021
	£	€	£	€
			as restated	as restated
Income from:				
Donations and legacies	22,472	25,341	31,230	37,186
Charitable activities	301,867	340,400	574,740	684,342
Investment income	<u>25</u>	<u>28</u>	<u>8</u>	<u>10</u>
Total income	<u>324,364</u>	<u>365,769</u>	<u>605,978</u>	<u>721,538</u>
Expenditure on:				
Charitable activities	<u>575,003</u>	<u>648,402</u>	<u>541,066</u>	<u>644,247</u>
Net (outgoing)/incoming resources	(250,639)	(282,633)	64,912	77,291
Other recognised gains and losses				
Other currency revaluation gains or losses	-	(21,893)	-	(10,532)
Other exchange gains or losses	<u>4,889</u>	<u>5,513</u>	<u>(23,425)</u>	<u>(27,892)</u>
Net movement in funds	(245,750)	(299,013)	41,487	38,874
Fund balances at 1 January 2022	<u>347,244</u>	<u>413,463</u>	<u>305,757</u>	<u>374,589</u>
Fund balances at 31 December 2022	<u>101,494</u>	<u>114,450</u>	<u>347,244</u>	<u>413,463</u>

This page does not form part of the statutory financial statements

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
BALANCE SHEET (EURO)**

AS AT 31 DECEMBER 2022

	2022	2022	2021	2021
			as restated	as restated
	£	€	£	€
Current assets				
Debtors	60,431	68,145	157,862	187,966
Cash at bank and in hand	<u>237,147</u>	<u>267,419</u>	<u>439,558</u>	<u>523,382</u>
	297,578	335,564	597,420	711,348
Creditors: amounts falling due within one year	<u>(196,084)</u>	<u>(221,114)</u>	<u>(250,176)</u>	<u>(297,885)</u>
Net current assets	<u>101,494</u>	<u>114,450</u>	<u>347,244</u>	<u>413,463</u>
Income funds				
Unrestricted funds	<u>101,494</u>	<u>114,450</u>	<u>347,244</u>	<u>413,463</u>
	<u>101,494</u>	<u>114,450</u>	<u>347,244</u>	<u>413,463</u>

This page does not form part of the statutory financial statements

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (EURO)

FOR THE YEAR ENDED 31 DECEMBER 2022

INCOME	Unrestricted funds	Unrestricted funds	Unrestricted funds	Unrestricted funds
	2022	2022	2021	2021
	£	€	£	€
Donations and legacies				
Donations and gifts	3,581	4,038	6,174	7,351
Membership fees	<u>18,891</u>	<u>21,303</u>	<u>25,056</u>	<u>29,834</u>
	<u>22,472</u>	<u>25,341</u>	<u>31,230</u>	<u>37,186</u>
Charitable activities			as restated	as restated
Core income	246,968	278,493	329,878	392,786
Project income	134,173	151,300	77,959	92,826
Other income	<u>(79,274)</u>	<u>(89,393)</u>	<u>166,903</u>	<u>198,731</u>
	<u>301,867</u>	<u>340,400</u>	<u>574,740</u>	<u>684,342</u>
Investment income				
Interest receivable	<u>25</u>	<u>28</u>	<u>8</u>	<u>10</u>

This page does not form part of the statutory financial statements

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (EURO)

FOR THE YEAR ENDED 31 DECEMBER 2022

EXPENDITURE	Unrestricted funds 2022 £	Unrestricted funds 2022 €	Unrestricted funds 2021 £ as restated	Unrestricted funds 2021 € as restated
Charitable activities				
Direct costs				
Member organisation and board meetings	15,636	17,632	39,480	47,011
Advocacy communication and project development	89,700	101,150	132,352	157,599
Funded projects	59,445	67,033	140,225	166,974
Other direct costs	407	459	103,368	123,063
Freelancer costs	<u>180,742</u>	<u>203,814</u>	<u>-</u>	<u>-</u>
	<u>345,930</u>	<u>390,088</u>	<u>415,425</u>	<u>494,647</u>
Support costs				
Staff costs	210,412	237,271	22,502	26,794
Technology costs	2,944	3,320	-	-
Fundraising	-	-	3,891	4,633
Bad debts	241	272	540	643
Bank charges	256	289	374	445
Financial administration	-	-	22,381	26,650
Bookkeeping costs	3,886	4,382	11,425	13,604
Consultancy fees	-	-	7,200	8,573
Other support costs	3,831	4,320	47,845	56,964
Travel costs	3,857	4,349	-	-
Insurance	1,076	1,213	-	-
Accountancy	1,370	1,545	7,483	8,910
Governance costs	<u>1,200</u>	<u>1,353</u>	<u>2,000</u>	<u>2,381</u>
	<u>229,073</u>	<u>258,314</u>	<u>125,641</u>	<u>149,600</u>

This page does not form part of the statutory financial statements

Accounts

REGISTERED COMPANY NUMBER: CE004367 (England and Wales)
REGISTERED CHARITY NUMBER: 1163211

Report of the Trustees and
Unaudited Financial Statements
for the Year Ended 31st December 2021
for
European Parkinson's Disease Association

A4G LLP
Kings Lodge
London Road
West Kingsdown
Sevenoaks
Kent
TN15 6AR

European Parkinson's Disease Association

Contents of the Financial Statements **for the Year Ended 31st December 2021**

	Page
Report of the Trustees	1 to 8
Independent Examiner's Report	9
Statement of Financial Activities	10
Statement of Financial Position	11 to 12
Statement of Cash Flows	13
Notes to the Statement of Cash Flows	14
Notes to the Financial Statements	15 to 25
Detailed Statement of Financial Activities	26 to 28

European Parkinson's Disease Association

Report of the Trustees **for the Year Ended 31st December 2021**

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31st December 2021. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

Introduction

2021 has seen once again the COVID-19 pandemic to cause continued uncertainty, impacting the EPDA and our member organisations, as well as the Parkinson's community as a whole. In spite of this, the EPDA has been able to achieve a series of remarkable results that will pave the way for **important developments** in 2022 and onwards.

In 2021, we consolidated the process to substantially improve the EPDA's **internal governance** - completing the reform of our Statutes with a focus on increased **inclusivity**. We also acquired a new member organisation and consistently increased and improved our communication with, and among, our members.

We continued to strengthen our relationships with the treatment industry, achieving a record number of **funding partners** and expanding in particular our collaboration with digital medical technology companies, and conducting win-win partnered projects benefiting the Parkinson's community directly.

After a slow-down due to the pandemic, our EU **advocacy** strategy is now being fully implemented. We have also been developing new EPDA **strategic projects** that are set to be carried out over the next three years - with an increased focus on research and the wellbeing of people with Parkinson's.

We have enlarged and deepened our relations with **Parkinson's stakeholders** in the global context - especially with the World Parkinson Congress and PD Avengers.

The EPDA also developed some impressive **online resources** (produced both independently and in partnership with the treatment industry) to provide information and support to the Parkinson's community on topics such as sleep, exercise, and nutrition.

Finally, the EPDA would not be where it is today without its members and its Board members. The EPDA Team would like to thank the EPDA Board members for contributing with their expertise, advice, and commitment to the positive results of the activities we will now describe in the following pages.

2022 is set to be an eventful year and we feel more than ready to embrace the opportunities and also the challenges as our groundwork has been set in 2021.

Governance

Statutes:

- o Amendments were proposed and ratified by the Board and the AGM in June 2021 pertaining to membership categories
- o Three membership categories were established:
 - Membership (Parkinson's) organisations
 - o Not for profit organisations based in any European country that represent a membership of people with Parkinson's and carers.
 - Affiliate
 - o Not for profit organisations who have a special interest in Parkinson's, with no individual members.
 - Friends
 - o For individuals, including people with Parkinson's, carers, healthcare professionals and other people with a particular interest in Parkinson's.

European Parkinson's Disease Association

Report of the Trustees **for the Year Ended 31st December 2021**

- o These changes allow for a greater inclusivity and enable the EPDA to benefit from the wealth of expertise and experience supplied by a wider membership.
- o Amends ratified at the EPDA AGM on 29 June 2021

Board:

- o Three new full Board members (former observers) elected by the AGM to serve for the next three years:
- o Gary Boyle - Ireland
- o Antonella Moretti - Parkinson Italia
- o Patricia Pérez Librero - Federacion Española de Parkinson

Results

- o A more inclusive EPDA, open to a more diverse membership
- o Improved expertise and representation in the Board

Membership

- o **One new member organisation** (MO) approved by the AGM in June 2021: Egas Moniz - Cooperativa de Ensino Superior, CRL - Portugal
- o Implementation of a **members grant scheme** and the awarding of the first three winners
- o Launch of a **weekly members e-shot**
- o Creation of a **membership strategy** for 2022 - with a strong focus on replicating successful projects carried out by EPDA MOs across different countries
- o **Virtual meetings** held with 21 EPDA MOs to discuss respective priorities, needs and areas for possible collaboration - involving the EPDA President and Vice-President, as well as the EPDA Director General and Membership Lead
- o **Membership benefits:**
 - Development of a simple brochure
 - Design of a new website page
- o Changes to **membership criteria** (see above) approved with a majority of votes by the EPDA AGM - amendment of the Affiliate Members category and introduction of the Friends category, aimed at individuals
- o One exclusive **communications workshop** aimed at MOs
- o Dissemination of Parkinson Italia's #UnmaskParkinsons **social media campaign:**
 - translation into seven languages
 - eight MOs inspired by the EPDA to run the campaign in their own countries
- o Two successful **members meetings:**
 - in times of COVID, we believed it was essential to work more closely with our members and highlight the fundamental work they do for the European Parkinson's community
 - the two members' meetings were held in virtual form and focused especially on:
 - developing opportunities for increased collaboration and sharing of good practices between the EPDA and our members
 - highlighting opportunities for our members to get involved in EPDA projects
 - showcasing examples of meaningful activities carried out by our members at national levels.

Results

- o A more inclusive EPDA open to a more diverse membership
- o Improved two-way communication between EPDA and MOs
- o Development of EPDA-member partnered activities on topics that are fundamental for the European Parkinson's community

Team improvements

A new:

- o Finance Manager
- o Projects Support Assistant
- o Research Manager (starting January 2022)

European Parkinson's Disease Association

Report of the Trustees **for the Year Ended 31st December 2021**

- o Team restructuring: **streamlining roles** for all Team members

Results:

- o Improved expertise within the Team
- o Increased our capacity to better respond to members' needs and also to engage in more projects in partnership with the treatment industry, and generally build relationships with the broader Parkinson's community
- o Smoother internal functioning

Treatment industry collaboration

Funding

- o 6 Diamond partners:
 - AbbVie
 - Boston Scientific
 - Britannia Pharmaceuticals
 - Kyowa Kirin
 - Merz Therapeutics
 - Sunovion
- o 5 Gold partners:
 - Abbott
 - Air Liquide
 - BIAL
 - Medtronic
 - Servier
- o 5 Silver partners:
 - Biogen
 - Roche
 - Theravance Biopharma
 - UCB
 - Zambon
- o 4 Tech partners:
 - Charco Neurotech
 - ConvaTec
 - GE Healthcare
 - Orbit Health
- o Foundations:
 - Boston Scientific Foundation Europe

Partnered projects include:

- o **Abbott:** development of a content campaign to raise awareness of the DBS options available to people with Parkinson's
- o **AbbVie:**
 - EPDA Board members supporting AbbVie in the development of its Parkinson's research investigations
 - EPDA Board members supporting AbbVie in the development of patient-focused information material
- o **Air Liquide:** carers' survey - dissemination of results in 2021
- o **Bial:**
 - collaboration with Bial on the dissemination of multimedia information materials and resources from the Keep it on website and online Training Area
 - continuation of the Keep ON Moving! dual-task video exercise project in collaboration with Bial
- o **Britannia Pharmaceuticals:**
 - development of a content campaign to raise awareness of advanced Parkinson's management and treatment options
 - development of a survey on advanced Parkinson's therapies awareness and information
- o **Kyowa Kirin:**

European Parkinson's Disease Association

Report of the Trustees **for the Year Ended 31st December 2021**

- participation of the EPDA in an advisory panel on patient organisations' engagement, organised by Kyowa Kirin
- development of a multimedia content campaign on wellbeing and the impact of the Coronavirus pandemic
- development of a virtual workshop meeting on healthcare professional education

o Medtronic:

- development of a webinar on DBS sensing technology
- development of a content campaign to raise awareness of advancement in DBS technology

o Merz: survey on sialorrhea (drooling) in Parkinson's - dissemination of results and planning of 2022 information and awareness activities on sialorrhea

o Servier: organisation of a workshop with people with Parkinson's, carers and advocates in collaboration with Servier

Results

- o Increased participation of the Parkinson's community (represented by the EPDA) in industry activities
- o Ultimately, the development of better treatment, support and care solutions for people with Parkinson's

Research

o Establishment of an EPDA Research Interest Group

- The Research Interest Group is open to all EPDA MOs and partners that are interested and passionate in becoming more active in Parkinson's research regardless of experience, skills, or knowledge.
- The group's goal is to provide a friendly forum to discuss and identify research gaps and needs and equip and enable EPDA members to engage in research and clinical trials.

o Successful delivery of two Patient Insight Workshops

- In March 2021, the EPDA collaborated with one of its Gold Partners (Servier) to run two virtual 'Patient Insight Workshops'.
- The aim of the workshops was to involve people with Parkinson's in the very early stages of the clinical trial design process in order to provide research teams with new approaches and ideas.
- Discussions focused on issues such as personalised therapy, improving communication with healthcare professionals, holistic approach to treatment, digital devices for monitoring Parkinson's, and a need to improve the efficacy and safety of existing symptomatic treatment.

Results

- o Increased involvement of the Parkinson's community (represented by the EPDA, EPDA members and Parkinson's advocates) in the planning and design of treatment research
- o Ultimately, the development of better treatment solutions for people with Parkinson's

Stakeholder engagement

o EPDA participation in WPC working groups: Six working groups set up by World Parkinson's Coalition Partners are developing a series of themed initiatives for the World Parkinson's Congress (WPC) 2023. In 2021, various members of the EPDA Board and staff participated in four of the working groups and supported the delivery of a virtual presentation at the WPC Leadership Forum in June 2021.

o Young-onset Parkinson's (YOPD) Working Group: this working group is co-chaired by Russell Patten (EPDA Director General) and Gaynor Edwards, supported by Adrien Moyroud (EPDA Project Support Assistant). The group is focused on developing a global survey for YOPD called PROMISE (Patient Research On Medication, Information, Symptoms & Experience). It has also created sub-groups to focus on genetics and women.

European Parkinson's Disease Association

Report of the Trustees **for the Year Ended 31st December 2021**

o **WPC Clinical Trials Working Group:** in 2021, Fiona Montague (EPDA Project Manager) and Dominic Graham (EPDA Operations Director) represented EPDA on the WPC Clinical Trials working group. The group has focused on identifying the barriers to accessing and taking part in research and exploring solutions with the aim of engaging more people with Parkinson's in clinical research and ensuring that each research opportunity is a good experience for all involved - regardless of the outcomes of the study. EPDA supported this work by surveying its member organisations to better understand the barriers to accessing and participating in research in different territories. The survey results were followed up by focus group discussions, which, in turn, led to the creation of the EPDA Research Interest Group (see above).

o **WPC Newly Diagnosed Working Group:** in 2021, Francesco De Renzis (EPDA Project Officer) represented the EPDA on the WPC Newly Diagnosed Working Group. The group has focused on identifying the barriers preventing people who are diagnosed with Parkinson's to engage with and seek support from Parkinson's patient organisations. The EPDA interviewed some of the EPDA members to gain a diverse, Europe-wide perspective on the topic. This resulted in identifying stigma as the main factor preventing people from seeking support; the group started exploring the possibility of developing an awareness campaign focused on stigma at a global level.

o **WPC Technology Working Group:** in 2021, EPDA President Veronica Clark represented the EPDA on the WPC Technology Working Group. The group goal is to explore existing technology that could improve life with Parkinson's and to promote innovative action, as well as to find areas of improvement that respond to unmet needs. The group is working towards developing a platform to increase access to technology services, and/or social networking that would provide better levels of care and help link people with Parkinson's, healthcare professionals and other stakeholders to technology options available.

Results

o Our growing relationship with the WPC is critical given on the one hand their tremendous value and outreach to the Parkinson's community and on the other the World Parkinson Congress to be held in Europe, on our doorstep, in 2023. By actively participating in some of the leading Working Groups, we have increased our involvement with the Parkinson's community in the planning and design of treatment research, the development of better treatment solutions for people with Parkinson's and enhancing the awareness of YOPD.

Advocacy

- o We ran **two workshops** that addressed why and how the EPDA needs to undertake political advocacy in EU-Brussels while also supporting actions carried out by EPDA members at national level.
- o With our **membership of the European Federation of Neurological Associations (EFNA)**, we have raised the profile of neurological diseases (NDs) in EU-Brussels with the support of many like-minded patient groups and the WHO. This has led to the first ever EU targeted action on NCDs - the 'Healthier Together' initiative - which will focus on neurological diseases in particular, with dedicated EU and national level support and funding streams, in 2023.
- o We have set up a new **Political Advocacy Working Group (PAGs)**, which will work with the EPDA Team to embark on an expanded scope of activities.
- o We have completed an in-depth **political stakeholder mapping** of all our key decision makers by country, which will support our MOs to work with EU decision makers in their respective countries and for the EPDA to build relationships with them in EU-Brussels.
- o We have undertaken a **perception survey**, which was carried out between September 2020 and September 2021 with 50 key EU-decision makers in Brussels on their perception/understanding of Parkinson's.
- o We submitted a **response to the European Commission's public consultation on the revision of the EU general pharmaceutical legislation**, due at the end of 2022. In the response, we highlighted that the new legislation should allow the EU and member states to take action to address shortages and availability, not only during times of crisis but also in the long-run to address this serious on-going issue.

Results

- o Raised the profile of the EPDA with policy-makers in the European institutions and with partner organisations
- o Increased awareness of the complexity of Parkinson's and the impact it has on people's quality of life
- o Ultimately, better policies and public interventions in support of people with Parkinson's, their families and carers

European Parkinson's Disease Association

Report of the Trustees **for the Year Ended 31st December 2021**

Sleep and Parkinson's awareness campaign

o **Overarching objective:** Provide and promote enhanced access and availability of sleep resources for people with Parkinson's, so they can make a more informed choice on how to improve their sleep.

Results

- o The campaign was a success and resonated well with people with Parkinson's.
- o Significant increase in engagement across all EPDA platforms as a result of the sleep content.
- o Feedback by a large majority was that the campaign was timely, interesting and of interest.
- o Involvement of several member organisations.
- o Coverage and reach of key messages on electronic media
 - 3,000+ web page views in May 2021
 - Average reach for Facebook posts: 4,000+ in May 2021
 - Total tweet reach: more than 364,000 in May 2021
 - Parkinson's Life articles that resonated with readers
 - Successful Touch NEUROLOGY online seminar
- o A full campaign evaluation document is available here.

Digital communication

- o Keep ON Moving! exercise video series 2 (created in collaboration with our partner, Bial)
- o World Parkinson's Day 2021 video (created in collaboration with our partner, Bial)
- o EPDA website
 - Traffic from more than 200 countries
 - High engagement to the About Parkinson's and Living Well sections
- o Parkinson's Life
 - Parkinson's Life podcast awarded Gold Award for 'Best Branded Podcast' at the 2021 International Content Marketing Awards
- o Social media channels
- o A new Instagram page set up in May 2021

Parkinson's and creativity

- o In 2021, the EPDA embarked on a journey to develop a **3D immersive arts experience** that focuses on the link between the brain, Parkinson's and creativity.
- o The goal of this project is to raise awareness, inspire and encourage exploration of **Parkinson's creativity**.
- o The EPDA is partnering with a range of stakeholders including digital and interactive design specialists, artists, neurologists and researchers to deliver an online platform and immersive experience that all our stakeholders across Europe will have the opportunity to participate in.

FINANCIAL REVIEW

Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

The Association's reserve policy is to hold reserves only to cover a period of 6 months administration costs. No additional reserves are intended to be held. Further analysis of restricted and unrestricted funds can be found in note 14.

European Parkinson's Disease Association

Report of the Trustees **for the Year Ended 31st December 2021**

STRUCTURE, GOVERNANCE AND MANAGEMENT

The charity was established by a charitable trust deed on 25th April 1998 in Belgium and registered as a Charitable Incorporated Organisation in the UK on 19th August 2015.

The trustees have had regard to the Charity Commission's guidance on public benefit.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

CE004367 (England and Wales)

Registered Charity number

1163211

Registered office

Kings Lodge
London Road
West Kingsdown
Sevenoaks
Kent
TN15 6AR

Trustees

Ms M E Graham
Ms V Clark
Mr D J Lavender MBE
Ms P Gilmore
J Domingos
C P Likar
T Shaish
Mr G Boyle (appointed 29.6.21)
Ms A Moretti (appointed 29.6.21)
Ms P P Librero (appointed 29.6.21)

Key management personnel

Mr R Patten, Director General
Mr D Graham, Operations Director
Mrs L Wong, Finance Manager

Independent Examiner

A4G LLP
Kings Lodge
London Road
West Kingsdown
Sevenoaks
Kent
TN15 6AR

Approved by order of the board of trustees on and signed on its behalf by:

European Parkinson's Disease Association

Report of the Trustees
for the Year Ended 31st December 2021

.....
Ms V Clark - Trustee

**Independent Examiner's Report to the Trustees of
European Parkinson's Disease Association**

Independent examiner's report to the trustees of European Parkinson's Disease Association ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31st December 2021.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a registered member of ICAEW which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Caroline Coleman ACA

A4G LLP
Kings Lodge
London Road
West Kingsdown
Sevenoaks
Kent
TN15 6AR

Date:

European Parkinson's Disease Association

Statement of Financial Activities **(Incorporating an Income and Expenditure Account)** **for the Year Ended 31st December 2021**

		Unrestricted funds	Restricted funds	2021 Total funds	2020 Total funds as restated
	Notes	£	£	£	£
INCOME AND ENDOWMENTS FROM					
Donations and legacies	4	31,230		31,230	28,283
Charitable activities	5				
Other income		121,703	45,200	166,903	-
Bank interest		8	-	8	174
Project Income		21,426	56,533	77,959	-
Core Income		261,386	68,492	329,878	531,508
Total		<u>435,752</u>	<u>170,226</u>	<u>605,978</u>	<u>559,965</u>
EXPENDITURE ON					
Charitable activities	6				
Member organisation and board meetings		39,480	-	39,480	22,762
Advocacy communication and project development		102,035	30,317	132,352	219,120
Grant Funded projects		662	139,563	140,225	78,108
Support costs		192,541	33,672	226,213	197,352
Governance costs		2,000	-	2,000	1,000
Other		(84,861)	109,082	24,221	9,055
Total		<u>251,857</u>	<u>312,634</u>	<u>564,491</u>	<u>527,397</u>
NET INCOME/(EXPENDITURE)		<u>183,895</u>	<u>(142,408)</u>	<u>41,487</u>	<u>32,568</u>
RECONCILIATION OF FUNDS					
Total funds brought forward					
As previously reported		11,650	323,597	335,247	302,679
Prior year adjustment	11	(29,490)	-	(29,490)	-
As restated		<u>(17,840)</u>	<u>323,597</u>	<u>305,757</u>	<u>302,679</u>
TOTAL FUNDS CARRIED FORWARD		<u><u>166,055</u></u>	<u><u>181,189</u></u>	<u><u>347,244</u></u>	<u><u>335,247</u></u>

The notes form part of these financial statements

European Parkinson's Disease Association

Statement of Financial Position **31st December 2021**

	Notes	2021 £	2020 as restated £
CURRENT ASSETS			
Debtors	12	157,862	133,500
Cash at bank and in hand		439,558	457,222
		<u>597,420</u>	<u>590,722</u>
CREDITORS			
Amounts falling due within one year	13	(250,176)	(255,475)
		<u>347,244</u>	<u>335,247</u>
NET CURRENT ASSETS			
		<u>347,244</u>	<u>335,247</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			
		<u>347,244</u>	<u>335,247</u>
NET ASSETS			
		<u>347,244</u>	<u>335,247</u>
FUNDS	15		
Unrestricted funds		166,054	11,650
Restricted funds		181,190	323,597
		<u>347,244</u>	<u>335,247</u>
TOTAL FUNDS			
		<u>347,244</u>	<u>335,247</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st December 2021.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st December 2021 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

The financial statements were approved by the Board of Trustees and authorised for issue on and were signed on its behalf by:

.....
Ms V Clark - Trustee

The notes form part of these financial statements

European Parkinson's Disease Association

Statement of Financial Position - continued
31st December 2021

.....
Mr D J Lavender MBE - Trustee

The notes form part of these financial statements

European Parkinson's Disease Association

Statement of Cash Flows
for the Year Ended 31st December 2021

		2021	2020
	Notes	£	as restated £
Cash flows from operating activities			
Cash generated from operations	1	<u>(17,664)</u>	<u>45,905</u>
Net cash (used in)/provided by operating activities		<u>(17,664)</u>	<u>45,905</u>
Change in cash and cash equivalents in the reporting period		(17,664)	45,905
Cash and cash equivalents at the beginning of the reporting period		<u>457,222</u>	<u>411,317</u>
Cash and cash equivalents at the end of the reporting period		<u><u>439,558</u></u>	<u><u>457,222</u></u>

The notes form part of these financial statements

European Parkinson's Disease Association

Notes to the Statement of Cash Flows
for the Year Ended 31st December 2021

1. RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2021	2020 as restated
	£	£
Net income for the reporting period (as per the Statement of Financial Activities)	41,487	32,568
Adjustments for:		
Prior year adjustments	(29,490)	-
Increase in debtors	(24,362)	(64,796)
(Decrease)/increase in creditors	(5,299)	78,133
Net cash (used in)/provided by operations	<u>(17,664)</u>	<u>45,905</u>

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1.1.21 £	Cash flow £	At 31.12.21 £
Net cash			
Cash at bank and in hand	457,222	(17,664)	439,558
	<u>457,222</u>	<u>(17,664)</u>	<u>439,558</u>
Total	<u>457,222</u>	<u>(17,664)</u>	<u>439,558</u>

The notes form part of these financial statements

European Parkinson's Disease Association

Notes to the Financial Statements **for the Year Ended 31st December 2021**

1. CHARITY INFORMATION

European Parkinson's Disease Association is a Charitable Incorporated Organisation registered in the UK on 19 August 2015.

2. ACCOUNTING POLICIES

Accounting convention

The accounts have been prepared in accordance with the charity's trust deed, the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016). The charity is a Public Benefit Entity as defined by FRS 102.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

Incoming resources

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

Turnover is measured at the fair value of the consideration received or receivable and represents amounts receivable for goods and services provided in the normal course of business, net of discounts, VAT and other sales related taxes.

Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

European Parkinson's Disease Association

Notes to the Financial Statements - continued **for the Year Ended 31st December 2021**

2. ACCOUNTING POLICIES - continued

Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation are included in net income/(expenditure for the period.

Leases

Rentals payable under operating leases, including any lease incentives received, are charged as an expense on a straight line basis over the term of the relevant lease.

European Parkinson's Disease Association

Notes to the Financial Statements - continued **for the Year Ended 31st December 2021**

2. ACCOUNTING POLICIES - continued

Irrecoverable vat

Irrecoverable VAT is charged against the expenditure heading for which it was incurred.

3. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

4. DONATIONS AND LEGACIES

	2021	2020 as restated
	£	£
Members fees	25,056	23,901
Donations	6,174	4,382
	<u>31,230</u>	<u>28,283</u>

5. INCOME FROM CHARITABLE ACTIVITIES

		2021	2020 as restated
	Activity	£	£
Other income	Other income	166,903	-
Bank interest	Bank interest	8	174
Project income	Project Income	77,959	-
Core income	Core Income	329,878	531,508
		<u>574,748</u>	<u>531,682</u>

European Parkinson's Disease Association

Notes to the Financial Statements - continued **for the Year Ended 31st December 2021**

6. CHARITABLE ACTIVITIES COSTS

	Direct Costs £	Support costs (see note 7) £	Totals £
Member organisation and board meetings	39,480	-	39,480
Advocacy communication and project development	132,352	-	132,352
Grant Funded projects	140,225	-	140,225
Support costs	103,368	122,845	226,213
Governance costs	-	2,000	2,000
	<u>415,425</u>	<u>124,845</u>	<u>540,270</u>

7. SUPPORT COSTS

	Management £	Finance £	Other £	Governance costs £	Totals £
Support costs	4,431	71,365	47,049	-	122,845
Governance costs	-	-	1,000	1,000	2,000
	<u>4,431</u>	<u>71,365</u>	<u>48,049</u>	<u>1,000</u>	<u>124,845</u>

Support costs, included in the above, are as follows:

	Support costs £	Governance costs £	2021 Total activities £	2020 as restated Total activities £
Advertising	-	-	-	3,142
Fundraising	3,891	-	3,891	5,637
Bad debts	540	-	540	-
Wages	22,502	-	22,502	25,099
Bank charges	374	-	374	178
Financial administration	22,381	-	22,381	30,818
Accountancy fees	5,057	-	5,057	5,000
Bookkeeping costs	7,160	-	7,160	4,000
Consultancy fees	7,200	-	7,200	-
Accountancy 2020	2,426	-	2,426	-
Bookkeeping 2020	4,265	-	4,265	-
General expenditure	14,766	-	14,766	12,714
Administration costs	32,283	-	32,283	44,918
Governance costs	-	1,000	1,000	-
Independent examination costs	-	1,000	1,000	1,000
	<u>122,845</u>	<u>2,000</u>	<u>124,845</u>	<u>132,506</u>

European Parkinson's Disease Association

Notes to the Financial Statements - continued **for the Year Ended 31st December 2021**

8. TRUSTEES' REMUNERATION AND BENEFITS

Ms M E Graham received fees totalling £26,008 (2020: £24,703) in connection with her role as strategic advisor. The payments have been made in accordance with the charity's constitution and approved by the other trustees.

Ms J Domingos received fees totalling £4,278 (2020: £nil) in connection with her role as project developer. The payments have been made in accordance with the charity's constitution and approved by the other trustees.

9. STAFF COSTS

	2021	2020 as restated
	£	£
Wages and salaries	22,502	25,099
	<u>22,502</u>	<u>25,099</u>

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

The average monthly number of employees/trustees during the year was as follows:

	2021	2020 as restated
Administration	2	2

The number of employees whose employees/trustees benefits (excluding employer pension costs) exceeded £60,000 was:

	2021	2020 as restated
£60,001 - £70,000	1	1

10. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted funds	Restricted funds	Total funds as restated
	£	£	£
INCOME AND ENDOWMENTS FROM			
Donations and legacies	28,283	-	28,283
Charitable activities			
Bank interest	174	-	174
Core Income	352,597	178,911	531,508
Total	<u>381,054</u>	<u>178,911</u>	<u>559,965</u>

EXPENDITURE ON

European Parkinson's Disease Association

Notes to the Financial Statements - continued **for the Year Ended 31st December 2021**

10. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued

	Unrestricted funds	Restricted funds	Total funds as restated
	£	£	£
Charitable activities			
Member organisation and board meetings	22,762	-	22,762
Advocacy communication and project development	213,615	5,505	219,120
Grant Funded projects	67,809	10,299	78,108
Support costs	186,018	11,334	197,352
Governance costs	1,000	-	1,000
Other	(1,887)	10,942	9,055
Total	489,317	38,080	527,397
NET INCOME/(EXPENDITURE)	(108,263)	140,831	32,568
RECONCILIATION OF FUNDS			
Total funds brought forward	119,912	182,767	302,679
TOTAL FUNDS CARRIED FORWARD	11,649	323,598	335,247

11. PRIOR YEAR ADJUSTMENT

There is a prior year adjustments in these accounts to correct the position of trade debtors and trade creditors of previous year. This ultimately decreased the retained earnings by £29,489.52.

Due to above adjustments and requirement of presentation, all the comparatives figures would be reflected as 'as restated'.

12. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2021	2020 as restated
	£	£
Trade debtors	150,017	120,397
Prepayments and accrued income	7,845	13,103
	<u>157,862</u>	<u>133,500</u>

European Parkinson's Disease Association

Notes to the Financial Statements - continued
for the Year Ended 31st December 2021

13. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2021	2020 as restated
	£	£
Trade creditors	78,336	68,718
Social security and other taxes	2,059	1,878
Fund deficits	8,075	-
Net wages	7,493	7,769
Pension	514	255
Accruals and deferred income	153,699	176,855
	<u>250,176</u>	<u>255,475</u>

14. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Unrestricted funds	Restricted funds	2021 Total funds	2020 as restated Total funds
	£	£	£	£
Current assets	408,155	189,265	597,420	590,722
Current liabilities	(242,101)	(8,075)	(250,176)	(255,475)
	<u>166,054</u>	<u>181,190</u>	<u>347,244</u>	<u>335,247</u>

European Parkinson's Disease Association**Notes to the Financial Statements - continued**
for the Year Ended 31st December 2021**15. MOVEMENT IN FUNDS**

	At 1.1.21 £	Prior year adjustment £	Net movement in funds £	At 31.12.21 £
Unrestricted funds				
General fund	11,561	(29,490)	183,204	165,275
AbbVie (neuroscience consultation)	-	-	690	690
Parkinson's Life	89	-	-	89
	<u>11,650</u>	<u>(29,490)</u>	<u>183,894</u>	<u>166,054</u>
Restricted funds				
PDCS	38,451	-	(38,451)	-
Research/Clinical trials	34,008	-	2,809	36,817
Parkinson's Information	-	-	561	561
Data Collection	12,367	-	(12,367)	-
Treat ER	87,706	-	(8,133)	79,573
European Young Onset PD	40,855	-	(40,855)	-
Advanced therapies	13,103	-	(13,103)	-
AirLiquide Carers Project	25,665	-	(25,665)	-
Parkinson's Life	-	-	(5,341)	(5,341)
Brain Life Goals	2,529	-	(2,529)	-
Bial	12,091	-	817	12,908
HCP Info/Educational Materials	8,786	-	(8,786)	-
Parkinson Sleep Project	27,252	-	(27,252)	-
Parkinson's Games	3,186	-	(5,920)	(2,734)
Tshipi's Art Exhibition	3,043	-	(3,043)	-
WPC Barcelona 2020	14,555	-	30,882	45,437
30th Anniversary	-	-	13,969	13,969
	<u>323,597</u>	<u>-</u>	<u>(142,407)</u>	<u>181,190</u>
TOTAL FUNDS	<u>335,247</u>	<u>(29,490)</u>	<u>41,487</u>	<u>347,244</u>

European Parkinson's Disease Association

Notes to the Financial Statements - continued **for the Year Ended 31st December 2021**

15. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	434,499	(251,295)	183,204
AbbVie (neuroscience consultation)	1,252	(562)	690
	<u>435,751</u>	<u>(251,857)</u>	<u>183,894</u>
Restricted funds			
PDCS	-	(38,451)	(38,451)
Research/Clinical trials	-	2,809	2,809
Parkinson's Information	4,302	(3,741)	561
Data Collection	-	(12,367)	(12,367)
Treat ER	-	(8,133)	(8,133)
European Young Onset PD	-	(40,855)	(40,855)
Advanced therapies	-	(13,103)	(13,103)
AirLiquide Carers Project	13,593	(39,258)	(25,665)
Parkinson's Life	104,573	(109,914)	(5,341)
Brain Life Goals	-	(2,529)	(2,529)
Bial	9,637	(8,820)	817
HCP Info/Educational Materials	-	(8,786)	(8,786)
Parkinson Sleep Project	-	(27,252)	(27,252)
Parkinson's Games	4,728	(10,648)	(5,920)
Tshipi's Art Exhibition	7,738	(10,781)	(3,043)
WPC Barcelona 2020	25,656	5,226	30,882
30th Anniversary	-	13,969	13,969
	<u>170,227</u>	<u>(312,634)</u>	<u>(142,407)</u>
TOTAL FUNDS	<u>605,978</u>	<u>(564,491)</u>	<u>41,487</u>

European Parkinson's Disease Association**Notes to the Financial Statements - continued**
for the Year Ended 31st December 2021**15. MOVEMENT IN FUNDS - continued****Comparatives for movement in funds**

	At 1.1.20 £	Net movement in funds £	At 31.12.20 £
Unrestricted funds			
General fund	124,112	(112,551)	11,561
Parkinson's Life	(4,200)	4,289	89
	119,912	(108,262)	11,650
Restricted funds			
PDCS	30,637	7,814	38,451
Research/Clinical trials	-	34,008	34,008
Parkinson's Information	7,487	(7,487)	-
Data Collection	12,498	(131)	12,367
Treat ER	91,752	(4,046)	87,706
European Young Onset PD	40,393	462	40,855
Advanced therapies	-	13,103	13,103
AirLiquide Carers Project	-	25,665	25,665
Brain Life Goals	-	2,529	2,529
Bial	-	12,091	12,091
HCP Info/Educational Materials	-	8,786	8,786
Parkinson Sleep Project	-	27,252	27,252
Parkinson's Games	-	3,186	3,186
Tshipi's Art Exhibition	-	3,043	3,043
WPC Barcelona 2020	-	14,555	14,555
	182,767	140,830	323,597
TOTAL FUNDS			
	302,679	32,568	335,247

European Parkinson's Disease Association

Notes to the Financial Statements - continued **for the Year Ended 31st December 2021**

15. MOVEMENT IN FUNDS - continued

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	315,855	(428,406)	(112,551)
Parkinson's Life	65,200	(60,911)	4,289
	<u>381,055</u>	<u>(489,317)</u>	<u>(108,262)</u>
Restricted funds			
PDCS	9,804	(1,990)	7,814
Research/Clinical trials	37,339	(3,331)	34,008
Parkinson's Information	2,247	(9,734)	(7,487)
Data Collection	-	(131)	(131)
Treat ER	-	(4,046)	(4,046)
European Young Onset PD	2,693	(2,231)	462
Advanced therapies	13,103	-	13,103
AirLiquide Carers Project	29,731	(4,066)	25,665
Brain Life Goals	2,705	(176)	2,529
Bial	15,721	(3,630)	12,091
HCP Info/Educational Materials	9,035	(249)	8,786
Parkinson Sleep Project	29,418	(2,166)	27,252
Parkinson's Games	4,260	(1,074)	3,186
Tshipi's Art Exhibition	3,361	(318)	3,043
WPC Barcelona 2020	19,493	(4,938)	14,555
	<u>178,910</u>	<u>(38,080)</u>	<u>140,830</u>
TOTAL FUNDS	<u>559,965</u>	<u>(527,397)</u>	<u>32,568</u>

The term 'restricted' refers to funds that have been allocated to a specific budget heading or project by the EPDA internally and are therefore not legally required to be restricted by a particular donor. It is at the charity's discretion whether they move fund between classes as appropriate.

16. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31st December 2021.

European Parkinson's Disease Association

Detailed Statement of Financial Activities **for the Year Ended 31st December 2021**

	Unrestricted funds	Restricted funds	2021 Total funds	2020 Total funds as restated
	£	£	£	£
INCOME AND ENDOWMENTS				
Donations and legacies				
Members fees	25,056	-	25,056	23,901
Donations	6,174	-	6,174	4,382
	31,229	-	31,230	28,283
Charitable activities				
Bank interest	8	-	8	174
Other income	121,703	45,200	166,903	-
Core income	261,385	68,493	329,878	531,508
Project income	21,426	56,533	77,959	-
	404,522	170,226	574,748	531,682
Total incoming resources				
	435,751	170,227	605,978	559,965
EXPENDITURE				
Charitable activities				
Members meeting	19,451	-	19,451	7,246
Administration Board	25,876	-	25,876	22,105
Website	13,671	420	14,091	9,690
Parkinson's life	-	102,598	102,598	72,009
Exhibitions	490	-	490	1,539
Communications	18,563	-	18,563	14,185
Social media	8,625	-	8,625	6,629
Digital strategy	5,234	-	5,234	6,083
Member organisation outreach	25,009	-	25,009	10,273
GDPR	325	-	325	540
PDCS	-	3,662	3,662	2,946
Research/clinical trials	-	6,008	6,008	3,331
Parkinson's info	-	3,511	3,511	2,836
Data collection	-	-	-	131
Treat ER	-	3,425	3,425	8,220
EYOPD	-	2,931	2,931	2,231
Advocacy	53,606	-	53,606	161,744
AirLiquide carers project	569	4,448	5,017	4,066
Adviser	16,398	-	16,398	16,194
Carried forward	187,817	127,003	314,820	351,998

This page does not form part of the statutory financial statements

European Parkinson's Disease Association**Detailed Statement of Financial Activities**
for the Year Ended 31st December 2021

	Unrestricted funds	Restricted funds	2021 Total funds	2020 Total funds as restated
	£	£	£	£
Charitable activities				
Brought forward	187,817	127,003	314,820	351,998
Prevalence	1,514	-	1,514	302
Merz (survey/HCP awareness)	-	3,646	3,646	3,017
Medtronic Awareness projects	-	950	950	309
HCP info/education materials	-	39	39	249
Awareness campaigns	4,158	-	4,158	2,202
Brain life goals	-	1,703	1,703	176
Bial's	-	7,475	7,475	3,630
Servier patient insights works	2,669	-	2,669	2,838
Kyowa kirin	4,336	-	4,336	289
Abbott	807	-	807	39
AbbVie	533	-	533	228
Boston affiliates	102	-	102	18
Britannia (awareness)	-	5,880	5,880	507
CMS	2,319	-	2,319	2,208
EPDA industry meeting	2,403	-	2,403	2,048
Industry partnered projects	5,043	-	5,043	3,177
Medtronic partnered project	-	93	93	147
NeuroPath EU project	-	-	-	612
Parkinson sleep project	-	18,909	18,909	2,166
Parkinson's games	-	10,499	10,499	1,074
Sunovion research project	172	-	172	3,346
Tshipi's art exhibition	-	18,784	18,784	318
WPC Barcelona	-	8,571	8,571	4,938
	211,873	203,552	415,425	385,836
Other				
Rent	796	-	796	1,326
Foreign exchange losses	5,995	17,430	23,425	7,729
	6,791	17,430	24,221	9,055
Support costs				
Management				
Advertising	-	-	-	3,142
Fundraising	3,891	-	3,891	5,637
Bad debts	540	-	540	-
	4,431	-	4,431	8,779
Finance				
Wages	22,502	-	22,502	25,099
Carried forward	22,502	-	22,502	25,099

This page does not form part of the statutory financial statements

European Parkinson's Disease Association**Detailed Statement of Financial Activities**
for the Year Ended 31st December 2021

	Unrestricted funds	Restricted funds	2021 Total funds	2020 Total funds as restated
	£	£	£	£
Finance				
Brought forward	22,502	-	22,502	25,099
Bank charges	374	-	374	178
Financial administration	22,381	-	22,381	30,818
Accountancy fees	5,057	-	5,057	5,000
Bookkeeping costs	7,160	-	7,160	4,000
Consultancy fees	7,200	-	7,200	-
Accountancy 2020	2,426	-	2,426	-
Bookkeeping 2020	4,265	-	4,265	-
	71,365	-	71,365	65,095
Other				
General expenditure	14,766	-	14,766	12,714
Administration costs	32,283	-	32,283	44,918
Governance costs	1,000	-	1,000	-
	48,049	-	48,049	57,632
Governance costs				
Independent examination costs	1,000	-	1,000	1,000
	343,509	220,982	564,491	527,397
Total resources expended				
Net income	92,242	(50,755)	41,487	32,568

This page does not form part of the statutory financial statements

European Parkinson's Disease Association

Statement of Financial Activities for the Year Ended 31st December 2021

	2021 (£)	2021 (€)	2020 (£)	2020 (€)
INCOME AND ENDOWMENTS				
Members Fees	25,056	29,834	23,904	26,709
Donations	6,174	7,351	4,379	4,893
	31,230	37,186	28,283	31,602
Charitable Activities				
Investments	8	10	174	194
Other income	166,903	198,731	-	-
Core income	329,878	392,786	531,508	593,882
Project income	77,959	92,826	-	-
	574,748	684,352	531,682	594,077
Total incoming resources	605,978	721,538	559,965	625,679
EXPENDITURE				
Charitable activities				
Members meeting	19,451	23,160	7,246	8,096
Administration Board	25,876	30,811	22,105	24,699
PDG think tank	-	-	-	2,566
Website	14,091	16,778	9,690	10,827
Parkinson's life	102,598	122,163	72,009	80,460
Exhibitions	490	583	1,539	1,720
Communications	18,563	22,103	14,185	15,850
Social Media	8,625	10,270	6,629	7,407
Digital strategy	5,234	6,232	6,083	6,797
Member organisation outreach	25,009	29,778	10,273	11,479
GDPR	325	387	540	603
PDCS	3,662	4,360	2,946	3,292
Research/clinical trials	6,008	7,154	3,331	3,720
Parkinson's info	3,511	4,181	2,836	3,169
Data collection	-	-	131	146
Treat ER	3,425	4,078	8,220	9,185
EYOPD	2,931	3,490	2,231	2,493
Advocacy	53,606	63,829	161,744	180,725
AirLiquide carers project	5,017	5,974	4,066	4,543
Adviser	16,398	19,525	16,194	18,094
Prevalence	1,514	1,803	302	337
Merz (survey/HCP awareness)	3,646	4,341	3,017	3,371
Medtronic Awareness projects	950	1,131	309	345
HCP info/education materials	39	46	249	278
Carried forward	320,969	382,178	355,875	397,638

This page does not form part of the statutory financial statements

European Parkinson's Disease Association

Statement of Financial Activities for the Year Ended 31st December 2021

Charitable activities

Brought forward	320,969	382,178	355,875	397,638
Awareness campaigns	4,158	4,951	2,202	2,460
Brain life goals	1,703	2,028	176	197
Bial's	7,475	8,900	3,630	4,056
Servier patient insights works	2,669	3,178	2,838	3,171
Kyowa kirin	4,336	5,163	289	323
Abbott	807	961	39	44
AbbVie	533	635	228	255
Boston affiliates	102	121	18	20
Britannia (awareness)	5,880	7,001	507	566
CMS	2,319	2,761	2,208	2,467
EPDA industry meeting	2,403	2,861	2,048	2,288
Industry partnered projects	5,043	6,005	3,177	3,550
Medtronic partnered project	93	111	147	164
NeuroPath EU project	-	-	612	684
Parkinson sleep project	18,909	22,515	2,166	2,420
Parkinson's games	10,499	12,501	1,074	1,200
Sunovion research project	172	205	3,346	3,739
Tshipi's art exhibition	18,784	22,366	318	355
WPC Barcelona	8,571	10,205	4,938	5,517

415,425	494,647	385,836	431,115
---------	---------	---------	---------

Other

Rent	796	948	1,326	1,482
------	-----	-----	-------	-------

Support costs

Management

Advertising	-	-	3,142	3,511
Bad debts	3,891	4,633	-	-
Fundraising	540	643	5,637	6,299
	4,431	5,276	8,779	9,809

Finance

Wages	22,502	26,793	25,099	28,044
Bank charges	374	445	178	199
Financial administration	22,381	26,649	30,818	34,435
Accountancy fees	5,057	6,021	5,000	5,587
Bookkeeping costs	7,160	8,525	4,000	4,469
Consultancy fees	7,200	8,573	-	-
Accountancy 2020	2,426	2,889	-	-
Bookkeeping 2020	4,265	5,078	-	-

71,365	84,974	65,095	72,734
--------	--------	--------	--------

Other

General expenditure	14,766	17,582	12,714	14,206
Administration costs	32,283	38,439	44,918	50,189

47,049	56,021	57,632	64,395
--------	--------	--------	--------

Governance costs

Independent examination costs	1,000	1,191	1,000	1,117
-------------------------------	-------	-------	-------	-------

European Parkinson's Disease Association

**Statement of Financial Activities for
the Year Ended 31st December 2021**

Total resources expended	<u>564,491</u>	<u>672,139</u>	<u>519,668</u>	<u>580,653</u>
Net income before gains and losses	64,912	77,291	40,297	45,026
Realised recognised gains and losses				
Realised gains/(losses) on fixed asset	<u>(23,425)</u>	<u>(27,892)</u>	<u>(7,729)</u>	<u>(8,636)</u>
Net income	<u>41,487</u>	<u>49,399</u>	<u>32,568</u>	<u>36,390</u>

European Parkinson's Disease Association**Statement of Financial Activities for
the Year Ended 31st December 2021**

	2021 (£)	2021 (€)	2020 (£)	2020 (€)
CURRENT ASSETS				
Debtors	157,862	187,966	133,500	149,167
Cash at bank and in hand	<u>439,558</u>	<u>523,382</u>	<u>457,222</u>	<u>510,879</u>
	597,420	711,348	590,722	660,045
CREDITORS				
Amounts falling due within one year	(250,176)	(297,885)	(255,475)	(285,456)
NET CURRENT ASSETS	<u>347,244</u>	<u>413,463</u>	<u>335,247</u>	<u>374,589</u>
TOTAL ASSETS LESS CURRENT LIABILITIES	347,244	413,463	335,247	374,589
NET ASSETS				
FUNDS				
Unrestricted funds	166,054	197,720	11,650	13,017
Restricted funds	<u>181,190</u>	<u>215,743</u>	<u>323,597</u>	<u>361,572</u>
TOTAL FUNDS	<u>347,244</u>	<u>413,463</u>	<u>335,247</u>	<u>374,589</u>

Parkinson's Europe

England & Wales - Charity number 1163211

Accounts

Report of the Trustees and
Unaudited Financial Statements
for the Year Ended 31st December 2020
for
European Parkinson's Disease Association

A4G LLP
Kings Lodge
London Road
West Kingsdown
Sevenoaks
Kent
TN15 6AR

Contents of the Financial Statements
for the Year Ended 31st December 2020

	Page
Report of the Trustees	1 to 5
Independent Examiner's Report	6
Statement of Financial Activities	7
Statement of Financial Position	8
Statement of Cash Flows	9
Notes to the Statement of Cash Flows	10
Notes to the Financial Statements	11 to 19
Detailed Statement of Financial Activities	20 to 22

European Parkinson's Disease Association

Report of the Trustees **for the Year Ended 31st December 2020**

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31st December 2020. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

Introduction

2020 has been a very difficult year for the whole world, and in particular organisations working in the non-profit sector - including many EPDA member organisations - have been hit particularly hard by the COVID-19 pandemic. In spite of this, the EPDA has been able to adapt to the 'new normal' and achieve a series of accomplishments that, we believe, allow us to lay the foundations for a positive post-COVID-19 outlook.

In the past 12 months, we completed the process to substantially improve the EPDA's internal governance - reforming our Statutes (with the help and collaboration of our Members) and striving for increased transparency and democracy. We also acquired new member organisations and started a process to improve and boost the two-way communication with our members - the first step being an important survey to better understand our members' opinions, needs and challenges.

We have continued to develop our relationships with the treatment industry, securing a record number of funding partners going into 2021 and engaging in a number of win-win partnered projects that will benefit the Parkinson's community - in many cases leading to better treatment options for people living with the condition.

We continued the roll-out of our EU advocacy strategy and developed new EPDA strategic projects that are set to be carried out over the next four years.

Last but not least, we produced and delivered some impressive online resources (developed both independently and in partnership with the treatment industry) to provide support to the Parkinson's community during the COVID-19 lockdown periods.

The EPDA Team would like to thank the EPDA Board members for contributing with their knowledge, expertise and constant commitment to the positive results of the projects and activities detailed below.

Governance

Statutes:

- o Amendments proposed and discussed in late 2019, voted by Members in early 2020
- o Most proposed amends approved by a majority of the Members
- o Statutes changes ratified by the AGM in September 2020
- o Amendment procedure to be finalised in 2021

Board:

- o A new President and Vice-President elected
- o Three new full Board members (former observers) elected by the AGM
- o Three new Board observers appointed in 2020

Results

- o Increased transparency and democracy
- o Smoother decision-making process and internal functioning
- o Improved expertise and representation in the Board

EPDA strategy

EPDA strategy reviewed by the EPDA Board at the end of 2020.

Four strategic goals still fit for purpose:

- a. To advocate for people with Parkinson's and their families to get the right information at the right time throughout their Parkinson's journey.
- b. To strive for healthcare systems where people with Parkinson's receive early and appropriate treatment and individualised care.
- c. To raise awareness of the complexity of Parkinson's and the impact it has on people's quality of life.

European Parkinson's Disease Association

Report of the Trustees **for the Year Ended 31st December 2020**

d. To support the global Parkinson's community in the search for a cure.

Three new strategic themes for the next three years:

- a. Uniting Europe
- b. Big data
- c. Research

Membership

Three new member organisations approved by the AGM in 2020

Member's survey

- o Most member organisations are 'satisfied' with being EPDA members
- o Most member organisations think the EPDA six-year strategy is fit for purpose
- o Most member organisations think the current level of communication with the EPDA is 'good' or 'excellent'

Completion of a set of guidelines aimed at Parkinson's organisations in the event of a shortage of medicines (this idea was initiated as a result of the panel discussion at the 2019 Members' Meeting)

Involvement of 18 member organisations in the WPC clinical trials survey, and eight in the subsequent in-depth conference calls

Members' Meeting 2020 (virtual): participation and engagement from 20 members

Member-specific activities being planned for 2021:

- o Exclusive EPDA member virtual roundtable events
- o EPDA membership grant scheme

Results

- o Improved two-way communication between EPDA and MOs
- o Development of EPDA-members partnered activities on topics that are fundamental for the European Parkinson's community

The EPDA would be delighted to hear about any initiatives from our members and partners that we could support, help advertise and promote, or advise on. If you need any help, please do get in touch and ask us!

Team improvements

A new Project Manager

A new Communications Lead

Team restructuring: increasing hours and streamlining roles and tasks for all Team members

Results

- o Improved expertise within the Team
- o Smoother internal functioning

EPDA exposure

High-profile international congresses:

- o Continued partnership and collaboration with WPC 2022, which will lead to very exciting EPDA-led activities in 2021 and 2022
- o MDS 2020: presentation of abstract about the EPDA-Air Liquide survey on the challenges of Parkinson's carers
- o INSIGHT into Parkinson's 2020: presentation on the EPDA survey on the challenges of Parkinson's carers

Medical/scientific journals:

- o Advertisements and highlights from our website and the Parkinson's Disease Composite Scale (Oruen, touchNeurology)

Results

Increased knowledge and awareness of the EPDA and Parkinson's in the medical/scientific community

Increased knowledge and awareness of the EPDA work in the Parkinson's community

Treatment industry collaboration

Funding (including work done in 2020 that has led to partnerships in 2021). Note: details below correct as at 8 February 2021

- o Diamond partners:
 - AbbVie (2020)

European Parkinson's Disease Association

Report of the Trustees **for the Year Ended 31st December 2020**

- Boston Scientific (2020 and 2021)
- Britannia Pharmaceuticals (2021)
- Kyowa Kirin (2021)
- Sunovion (2020 and 2021)
- o Gold partners:
 - Abbott (2021)
 - Air Liquide (2020 and 2021)
 - BIAL (2020 and 2021)
 - Medtronic (2020 and 2021)
 - Merz (2020 and 2021)
 - Servier (2021)
 - UCB (2020)
- o Silver partners:
 - Biogen (2021)
 - EverPharma (2020)
 - Servier (2020)
 - Theravance Biopharma (2021)
 - UCB (2021)
 - Zambon (2020 and 2021)
- o Tech partners:
 - GE Healthcare (2020)
 - Insightec (2020)
- o Other partners:
 - Herantis (2020)
 - Lundbeck (2020)

Partnered projects include:

- o **Abbott:** development of a content campaign to raise awareness of the DBS options available to people with Parkinson's
- o **AbbVie:** EPDA Board members supporting AbbVie in the development of its Parkinson's research investigations
- o **Air Liquide:** carers' survey (dissemination of results in 2020 and 2021)
- o **Bial:** collaboration with BIAL on the Keep it ON video awareness campaign, developing a series of awareness videos involving people with Parkinson's from five European countries
- o **Bial:** development of the Keep ON Moving! dual-task video exercise project in collaboration with BIAL
- o **Britannia Pharmaceuticals:** development of a content campaign to raise awareness of the non-oral treatment options available to people with Parkinson's
- o **Herantis and TreatER:** EU-funded project concluded and results published in a virtual webinar held in November 2020
- o **Kyowa Kirin:** participation of the EPDA in an advisory panel on patient organisations engagement organised by Kyowa Kirin
- o **Medtronic:** support of Medtronic's new Percept device launch, and review of World Parkinson's Day awareness materials
- o **Merz:** survey on sialorrhea in Parkinson's developed in collaboration with Merz (carried out in 2020, results expected in 2021)
- o **Servier:** organisation of a workshop with people with Parkinson's, carers and advocates (preparation in 2020, virtual workshop to be held in 2021) in collaboration with Servier
- o **Sunovion:** awareness communication campaign on Sunovion's clinical trial of sublingual apomorphine - developed in 2020, to be launched in early 2021

Results

Increased participation of the Parkinson's community (represented by the EPDA) in industry activities
Ultimately, the development of better treatment, support and care solutions for people with Parkinson's

Research

- TreatER project
 - o Long-time collaboration with Herantis Pharma and lead academic universities
 - o Started in 2017
 - o Results presented at a virtual scientific conference in November 2020

Sunovion CTH-302 trial

- o Collaboration with treatment company and research institutions in six European countries

European Parkinson's Disease Association

Report of the Trustees **for the Year Ended 31st December 2020**

- o Raising awareness of the clinical trial opportunities available to the Parkinson's community

Servier clinical trial design

- o Involving the Parkinson's community in the guiding, planning, design and development of Servier's upcoming clinical trial
- o Organisation of a collaborative workshop with people with Parkinson's, carers and patient advocates

WPC clinical trials interest group

- o Working with Parkinson's associations from around the world on surveys and conference calls in order to gather information about the barriers and opportunities for Parkinson's communities interested in getting involved in research

Results

Increased involvement of the Parkinson's community (represented by the EPDA, EPDA members and Parkinson's advocates) in the planning and design of treatment research

More inclusive, effective and patient-friendly clinical trials

Ultimately, the development of better treatment solutions for people with Parkinson's

Advocacy

2020 was the year to prepare the ground for the EPDA's outreach for the next four years. A new EU came into power in 2020 and we have been assessing how they view health and indeed whether they know about Parkinson's.

We are completing an in-depth political mapping of who's who in the Institutions directly but also indirectly influencing/impacting health policy. We have undertaken a decision-makers survey to assess their understanding of the disease and we have reached out to them to both introduce ourselves and to lay out our needs and asks.

We have developed a number of hooks for future advocacy campaigning in EU-Brussels around the role of carers as a follow-up to the EPDA/Air Liquide survey; around the role of pesticides and their impact on Parkinson's, and most recently on the EU's review of the pharmaceutical industry which will be a on-going issue for the year to come, looking at, for example, equal access to medicines, shortages of medicines, and many other key topics

The EPDA has been engaged closely with EFNA and played a role in developing their strategy for the Brain, Mind and Pain EP intergroup

We have developed the EU-Brussels Political Advocacy bi-monthly newsletter aimed at member organisations and other EPDA stakeholders

Ongoing support to the PD Avengers advocacy group throughout 2020 and into 2021

Results

Increased awareness of the complexity of Parkinson's and the impact it has on people's quality of life

Ultimately, better policies and public interventions in support of people with Parkinson's, their families and carers

Resources and digital communication

Sleep and Parkinson's awareness campaign: initiated in Q4 2020 and to be launched in 2021

EPDA Exercise Cast: our own online video exercise series for people with Parkinson's (which led directly to the incredibly successful Keep ON Moving! exercise video series we created in collaboration with our partner, Bial)

#BrainLifeGoals: educational video for HCPs focusing on cognitive-motor exercise programmes

EPDA website

- o Nearly 370,000 users and more than 850,000 page views
- o Traffic from more than 200 countries
- o High engagement to the About Parkinson's and Living Well sections

Parkinson's Life

o Parkinson's Life podcast awarded 'Best Global Audio Campaign of the Year' at the Global Content Awards 2020

o Nearly 270,000 users and 400,000 page views

EPDA strategic communications review - initiated in 2020, due to be finalised and implemented in 2021

Results

o Increased awareness of the complexity of Parkinson's and the impact it has on people's quality of life

o Delivery of high-quality information and resources to the Parkinson's community

European Parkinson's Disease Association

Report of the Trustees **for the Year Ended 31st December 2020**

FINANCIAL REVIEW

Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

The Association's reserve policy is to hold reserves only to cover a period of 6 months administration costs. No additional reserves are intended to be held. Further analysis of restricted and unrestricted funds can be found in note 14.

STRUCTURE, GOVERNANCE AND MANAGEMENT

The charity was established by a charitable trust deed on 25th April 1998 in Belgium and registered as a Charitable Incorporated Organisation in the UK on 19th August 2015.

The trustees have had regard to the Charity Commission's guidance on public benefit.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

CE004367 (England and Wales)

Registered Charity number

1163211

Registered office

Kings Lodge
London Road
West Kingsdown
Sevenoaks
Kent
TN15 6AR

Trustees

Mr K Onarheim (resigned 1.9.20)
Ms M E Graham
Ms S Lindvall (resigned 1.9.20)
Ms V Clark
Mr D J Lavender MBE
Ms V A Buxton
Ms P Gilmore
J Domingos (appointed 1.9.20)
C P Likar (appointed 1.9.20)
T Shaish (appointed 1.9.20)

Independent Examiner

A4G LLP
Kings Lodge
London Road
West Kingsdown
Sevenoaks
Kent
TN15 6AR

Approved by order of the board of trustees on and signed on its behalf by:

.....
Ms V Clark - Trustee

**Independent Examiner's Report to the Trustees of
European Parkinson's Disease Association**

Independent examiner's report to the trustees of European Parkinson's Disease Association ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31st December 2020.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a registered member of ACA which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Caroline Coleman
ACA
A4G LLP
Kings Lodge
London Road
West Kingsdown
Sevenoaks
Kent
TN15 6AR

Date:

European Parkinson's Disease Association

Statement of Financial Activities **(Incorporating an Income and Expenditure Account)** **for the Year Ended 31st December 2020**

	Notes	Unrestricted funds £	Restricted funds £	2020 Total funds £	2019 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies	4	28,283	-	28,283	26,626
Charitable activities	5				
Member organisation and board meetings		-	-	-	22,374
Other income		-	-	-	1,895
Investments		174	-	174	313
Publications		-	-	-	6,774
Project Income		-	-	-	52,557
Core Income		352,597	178,911	531,508	255,664
Total		<u>381,054</u>	<u>178,911</u>	<u>559,965</u>	<u>366,203</u>
EXPENDITURE ON					
Charitable activities	6				
Member organisation and board meetings		22,762	-	22,762	40,223
Advocacy communication and project development		213,615	5,505	219,120	72,356
Grant Funded projects		67,809	10,299	78,108	100,025
Support costs		186,018	11,334	197,352	129,098
Governance costs		1,000	-	1,000	1,000
Other		<u>1,326</u>	<u>-</u>	<u>1,326</u>	<u>-</u>
Total		<u>492,530</u>	<u>27,138</u>	<u>519,668</u>	<u>342,702</u>
Net gains/(losses) on investments		<u>3,213</u>	<u>(10,942)</u>	<u>(7,729)</u>	<u>(2,285)</u>
NET INCOME/(EXPENDITURE)		<u>(108,263)</u>	<u>140,831</u>	<u>32,568</u>	<u>21,216</u>
RECONCILIATION OF FUNDS					
Total funds brought forward		<u>119,912</u>	<u>182,767</u>	<u>302,679</u>	<u>281,463</u>
TOTAL FUNDS CARRIED FORWARD		<u><u>11,649</u></u>	<u><u>323,598</u></u>	<u><u>335,247</u></u>	<u><u>302,679</u></u>

The notes form part of these financial statements

European Parkinson's Disease Association

Statement of Financial Position
31st December 2020

	Notes	2020 £	2019 £
CURRENT ASSETS			
Debtors	11	133,500	68,704
Cash at bank and in hand		<u>457,222</u>	<u>411,317</u>
		590,722	480,021
CREDITORS			
Amounts falling due within one year	12	(255,475)	(177,342)
		<u>335,247</u>	<u>302,679</u>
NET CURRENT ASSETS			
		<u>335,247</u>	<u>302,679</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>335,247</u>	<u>302,679</u>
NET ASSETS		<u>335,247</u>	<u>302,679</u>
FUNDS	14		
Unrestricted funds		11,650	119,912
Restricted funds		<u>323,597</u>	<u>182,767</u>
TOTAL FUNDS		<u>335,247</u>	<u>302,679</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st December 2020.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st December 2020 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

The financial statements were approved by the Board of Trustees and authorised for issue on
and were signed on its behalf by:

.....
Ms V Clark - Trustee

.....
Mr D J Lavender MBE - Trustee

The notes form part of these financial statements

European Parkinson's Disease Association

Statement of Cash Flows
for the Year Ended 31st December 2020

	Notes	2020 £	2019 £
Cash flows from operating activities			
Cash generated from operations	1	<u>53,634</u>	<u>28,365</u>
Net cash provided by operating activities		<u>53,634</u>	<u>28,365</u>
Cash flows from investing activities			
Sale of fixed asset investments		<u>(7,729)</u>	<u>(2,285)</u>
Net cash used in investing activities		<u>(7,729)</u>	<u>(2,285)</u>
Change in cash and cash equivalents in the reporting period		45,905	26,080
Cash and cash equivalents at the beginning of the reporting period		<u>411,317</u>	<u>385,237</u>
Cash and cash equivalents at the end of the reporting period		<u><u>457,222</u></u>	<u><u>411,317</u></u>

The notes form part of these financial statements

Notes to the Statement of Cash Flows
for the Year Ended 31st December 2020

1. RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2020	2019
	£	£
Net income for the reporting period (as per the Statement of Financial Activities)	32,568	21,216
Adjustments for:		
Losses on investments	7,729	2,285
(Increase)/decrease in debtors	(64,796)	20,936
Increase/(decrease) in creditors	<u>78,133</u>	<u>(16,072)</u>
Net cash provided by operations	<u>53,634</u>	<u>28,365</u>

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1.1.20	Cash flow	At 31.12.20
	£	£	£
Net cash			
Cash at bank and in hand	<u>411,317</u>	<u>45,905</u>	<u>457,222</u>

Notes to the Financial Statements
for the Year Ended 31st December 2020

1. CHARITY INFORMATION

European Parkinson's Disease Association is a Charitable Incorporated Organisation registered in the UK on 19 August 2015.

2. ACCOUNTING POLICIES

Accounting convention

The accounts have been prepared in accordance with the charity's trust deed, the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016). The charity is a Public Benefit Entity as defined by FRS 102.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

Incoming resources

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

Turnover is measured at the fair value of the consideration received or receivable and represents amounts receivable for goods and services provided in the normal course of business, net of discounts, VAT and other sales related taxes.

Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Notes to the Financial Statements - continued
for the Year Ended 31st December 2020

2. ACCOUNTING POLICIES - continued

Financial instruments

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation are included in net income/(expenditure for the period).

Leases

Rentals payable under operating leases, including any lease incentives received, are charged as an expense on a straight line basis over the term of the relevant lease.

Irrecoverable vat

Irrecoverable VAT is charged against the expenditure heading for which it was incurred.

Notes to the Financial Statements - continued
for the Year Ended 31st December 2020

3. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

4. DONATIONS AND LEGACIES

	2020	2019
	£	£
Members fees	23,904	24,408
Donations	<u>4,379</u>	<u>2,218</u>
	<u>28,283</u>	<u>26,626</u>

5. INCOME FROM CHARITABLE ACTIVITIES

	2020	2019
	£	£
Member organisation meeting	-	22,374
Other income	-	1,895
Investments	174	313
Publication income	-	6,774
Project income	-	52,557
Core income	<u>531,508</u>	<u>255,664</u>
	<u>531,682</u>	<u>339,577</u>

6. CHARITABLE ACTIVITIES COSTS

	Direct Costs	Support costs (see note 7)	Totals
	£	£	£
Member organisation and board meetings	22,762	-	22,762
Advocacy communication and project development	215,978	3,142	219,120
Grant Funded projects	78,108	-	78,108
Support costs	68,988	128,364	197,352
Governance costs	<u>-</u>	<u>1,000</u>	<u>1,000</u>
	<u>385,836</u>	<u>132,506</u>	<u>518,342</u>

**Notes to the Financial Statements - continued
for the Year Ended 31st December 2020**

7. SUPPORT COSTS

	Management £	Finance £	Other £	Governance costs £	Totals £
Advocacy communication and project development	3,142	-	-	-	3,142
Support costs	5,637	65,095	57,632	-	128,364
Governance costs	-	-	-	1,000	1,000
	<u>8,779</u>	<u>65,095</u>	<u>57,632</u>	<u>1,000</u>	<u>132,506</u>

Support costs, included in the above, are as follows:

				2020	2019
	Advocacy communication and project development £	Support costs £	Governance costs £	Total activities £	Total activities £
Advertising	3,142	-	-	3,142	-
Fundraising	-	5,637	-	5,637	14,926
Wages	-	25,099	-	25,099	8,693
Bank charges	-	178	-	178	-
Financial administration	-	30,818	-	30,818	15,326
Accountancy fees	-	5,000	-	5,000	4,760
Bookkeeping costs	-	4,000	-	4,000	-
General expenditure	-	12,714	-	12,714	13,062
Administration costs	-	44,918	-	44,918	8,436
Independent examination costs	-	-	1,000	1,000	1,000
	<u>3,142</u>	<u>128,364</u>	<u>1,000</u>	<u>132,506</u>	<u>66,203</u>

8. TRUSTEES' REMUNERATION AND BENEFITS

Ms M E Graham received fees totalling £24,703 (2019: £16,747) in connection with her role as strategic advisor. The payments have been made in accordance with the charity's constitution and approved by the other trustees.

9. STAFF COSTS

	2020 £	2019 £
Wages and salaries	<u>25,099</u>	<u>8,693</u>
	<u>25,099</u>	<u>8,693</u>

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

The average monthly number of employees during the year was as follows:

	2020	2019
Administration	<u>2</u>	<u>2</u>

Notes to the Financial Statements - continued
for the Year Ended 31st December 2020

9. STAFF COSTS - continued

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2020	2019
£60,001 - £70,000	<u>1</u>	<u>-</u>

10. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted funds £	Restricted funds £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	26,628	(2)	26,626
Charitable activities			
Member organisation and board meetings	22,374	-	22,374
Other income	1,895	-	1,895
Investments	313	-	313
Publications	6,774	-	6,774
Project Income	39,316	13,241	52,557
Core Income	174,249	81,415	255,664
Total	271,549	94,654	366,203
EXPENDITURE ON			
Charitable activities			
Member organisation and board meetings	40,223	-	40,223
Advocacy communication and project development	72,356	-	72,356
Grant Funded projects	4,200	95,825	100,025
Support costs	126,880	2,218	129,098
Governance costs	1,000	-	1,000
Total	244,659	98,043	342,702
Net gains/(losses) on investments	<u>(2,285)</u>	<u>-</u>	<u>(2,285)</u>
NET INCOME/(EXPENDITURE)	24,605	(3,389)	21,216
RECONCILIATION OF FUNDS			
Total funds brought forward	95,309	186,154	281,463
TOTAL FUNDS CARRIED FORWARD	<u>119,914</u>	<u>182,765</u>	<u>302,679</u>

Notes to the Financial Statements - continued
for the Year Ended 31st December 2020

11. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2020	2019
	£	£
Trade debtors	120,397	68,477
Prepayments and accrued income	<u>13,103</u>	<u>227</u>
	<u>133,500</u>	<u>68,704</u>

12. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2020	2019
	£	£
Trade creditors	68,718	43,913
Social security and other taxes	1,878	5,637
Net wages	7,769	5,568
Pension	255	256
Accruals and deferred income	<u>176,855</u>	<u>121,968</u>
	<u>255,475</u>	<u>177,342</u>

13. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Unrestricted funds £	Restricted funds £	2020 Total funds £	2019 Total funds £
Current assets	267,125	323,597	590,722	480,021
Current liabilities	<u>(255,475)</u>	<u>-</u>	<u>(255,475)</u>	<u>(177,342)</u>
	<u>11,650</u>	<u>323,597</u>	<u>335,247</u>	<u>302,679</u>

Notes to the Financial Statements - continued
for the Year Ended 31st December 2020

14. MOVEMENT IN FUNDS

	At 1.1.20 £	Net movement in funds £	At 31.12.20 £
Unrestricted funds			
General fund	124,112	(112,551)	11,561
Parkinson's Life	<u>(4,200)</u>	<u>4,289</u>	<u>89</u>
	119,912	(108,262)	11,650
Restricted funds			
PDCS	30,637	7,814	38,451
Research/Clinical trials	-	34,008	34,008
Parkinson's Information	7,487	(7,487)	-
Data Collection	12,498	(131)	12,367
Treat ER	91,752	(4,046)	87,706
European Young Onset PD	40,393	462	40,855
Advanced therapies	-	13,103	13,103
AirLiquide Carers Project	-	25,665	25,665
Brain Life Goals	-	2,529	2,529
Bial	-	12,091	12,091
HCP Info/Educational Materials	-	8,786	8,786
Parkinson Sleep Project	-	27,252	27,252
Parkinson's Games	-	3,186	3,186
Tshipi's Art Exhibition	-	3,043	3,043
WPC Barcelona 2020	<u>-</u>	<u>14,555</u>	<u>14,555</u>
	<u>182,767</u>	<u>140,830</u>	<u>323,597</u>
TOTAL FUNDS	<u>302,679</u>	<u>32,568</u>	<u>335,247</u>

European Parkinson's Disease Association

Notes to the Financial Statements - continued for the Year Ended 31st December 2020

14. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	315,855	(424,721)	(3,685)	(112,551)
Parkinson's Life	<u>65,200</u>	<u>(67,809)</u>	<u>6,898</u>	<u>4,289</u>
	381,055	(492,530)	3,213	(108,262)
Restricted funds				
PDCS	9,804	(1,992)	2	7,814
Research/Clinical trials	37,339	(3,331)	-	34,008
Parkinson's Information	2,247	(2,836)	(6,898)	(7,487)
Data Collection	-	(131)	-	(131)
Treat ER	-	-	(4,046)	(4,046)
European Young Onset PD	2,693	(2,231)	-	462
Advanced therapies	13,103	-	-	13,103
AirLiquide Carers Project	29,731	(4,066)	-	25,665
Brain Life Goals	2,705	(176)	-	2,529
Bial	15,721	(3,630)	-	12,091
HCP Info/Educational Materials	9,035	(249)	-	8,786
Parkinson Sleep Project	29,418	(2,166)	-	27,252
Parkinson's Games	4,260	(1,074)	-	3,186
Tshipi's Art Exhibition	3,361	(318)	-	3,043
WPC Barcelona 2020	<u>19,493</u>	<u>(4,938)</u>	<u>-</u>	<u>14,555</u>
	<u>178,910</u>	<u>(27,138)</u>	<u>(10,942)</u>	<u>140,830</u>
TOTAL FUNDS	<u>559,965</u>	<u>(519,668)</u>	<u>(7,729)</u>	<u>32,568</u>

Comparatives for movement in funds

	At 1.1.19 £	Net movement in funds £	At 31.12.19 £
Unrestricted funds			
General fund	95,309	28,803	124,112
Parkinson's Life	<u>-</u>	<u>(4,200)</u>	<u>(4,200)</u>
	95,309	24,603	119,912
Restricted funds			
PDCS	51,115	(20,478)	30,637
Parkinson's Information	1,168	6,319	7,487
Data Collection	12,498	-	12,498
Treat ER	91,752	-	91,752
European Young Onset PD	<u>29,621</u>	<u>10,772</u>	<u>40,393</u>
	<u>186,154</u>	<u>(3,387)</u>	<u>182,767</u>
TOTAL FUNDS	<u>281,463</u>	<u>21,216</u>	<u>302,679</u>

Notes to the Financial Statements - continued
for the Year Ended 31st December 2020

14. MOVEMENT IN FUNDS - continued

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	271,547	(240,459)	(2,285)	28,803
Parkinson's Life	-	(4,200)	-	(4,200)
	271,547	(244,659)	(2,285)	24,603
Restricted funds				
PDCS	-	(20,478)	-	(20,478)
Parkinson's Information	8,696	(2,377)	-	6,319
European Young Onset PD	13,103	(2,331)	-	10,772
Advanced therapies	13,103	(13,103)	-	-
AirLiquide Carers Project	2,444	(2,444)	-	-
Parkinson's Life	57,310	(57,310)	-	-
	94,656	(98,043)	-	(3,387)
TOTAL FUNDS	<u>366,203</u>	<u>(342,702)</u>	<u>(2,285)</u>	<u>21,216</u>

15. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31st December 2020.

European Parkinson's Disease Association

Detailed Statement of Financial Activities **for the Year Ended 31st December 2020**

	2020 £	2019 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Members fees	23,904	24,408
Donations	<u>4,379</u>	<u>2,218</u>
	28,283	26,626
Charitable activities		
Member organisation meeting	-	22,374
Publication income	-	6,774
Investments	174	313
Other income	-	1,895
Core income	531,508	255,664
Project income	<u>-</u>	<u>52,557</u>
	<u>531,682</u>	<u>339,577</u>
Total incoming resources	559,965	366,203
EXPENDITURE		
Charitable activities		
Members meeting	7,246	38,052
Administration Board	22,105	31,991
PDG think tank	-	2,171
Website	9,690	7,922
Parkinson's life	72,009	58,392
Exhibitions	1,539	12,999
Communications	14,185	10,050
Social media	6,629	20,470
Digital strategy	6,083	10,228
Member organisation outreach	10,273	11,934
GDPR	540	1,076
PDCS	2,946	28,089
Research/clinical trials	3,331	1,550
Parkinson's info	2,836	2,748
Data collection	131	1,812
Global campaign	-	2,404
Treat ER	8,220	250
EYOPD	2,231	2,380
Advocacy	161,744	1,877
AirLiquide carers project	4,066	28,557
Adviser	16,194	1,547
Prevalence	302	-
Merz (survey/HCP awareness)	3,017	-
Medtronic Awareness projects	309	-
HCP info/education materials	249	-
Carried forward	355,875	276,499

This page does not form part of the statutory financial statements

European Parkinson's Disease Association**Detailed Statement of Financial Activities**
for the Year Ended 31st December 2020

	2020 £	2019 £
Charitable activities		
Brought forward	355,875	276,499
Awareness campaigns	2,202	-
Brain life goals	176	-
Bial's	3,630	-
Servier patient insights works	2,838	-
Kyowa kirin	289	-
Abbott	39	-
AbbVie	228	-
Boston affiliates	18	-
Britannia (awareness)	507	-
CMS	2,208	-
EPDA industry meeting	2,048	-
Industry partnered projects	3,177	-
Medtronic partnered project	147	-
NeuroPath EU project	612	-
Parkinson sleep project	2,166	-
Parkinson's games	1,074	-
Sunovion research project	3,346	-
Tshipi's art exhibition	318	-
WPC Barcelona	4,938	-
	385,836	276,499
Other		
Rent	1,326	-
Support costs		
Management		
Advertising	3,142	-
Fundraising	5,637	14,926
	8,779	14,926
Finance		
Wages	25,099	8,693
Bank charges	178	-
Financial administration	30,818	15,326
Accountancy fees	5,000	4,760
Bookkeeping costs	4,000	-
	65,095	28,779
Other		
General expenditure	12,714	13,062
Administration costs	44,918	8,436
	57,632	21,498
Governance costs		
Independent examination costs	1,000	1,000

This page does not form part of the statutory financial statements

European Parkinson's Disease Association

Detailed Statement of Financial Activities
for the Year Ended 31st December 2020

	2020 <u>£</u>	2019 <u>£</u>
Total resources expended	<u>519,668</u>	<u>342,702</u>
Net income before gains and losses	40,297	23,501
Realised recognised gains and losses		
Realised gains/(losses) on fixed asset investments	<u>(7,729)</u>	<u>(2,285)</u>
Net income	<u><u>32,568</u></u>	<u><u>21,216</u></u>

**Statement of Financial Activities for
the Year Ended 31st December 2020**

	2020 (£)	2020 (€)	2019 (£)	2019 (€)
INCOME AND ENDOWMENTS				
Donations				
Members Fees	23,904	26,709	24,408	28,844
Donations	<u>4,379</u>	<u>4,893</u>	<u>2,218</u>	<u>2,621</u>
	28,283	31,602	26,626	31,465
Charitable Activities				
Member organisation meeting	-	-	22,374	26,440
Publication Income	-	-	6,774	8,005
Investments	174	194	313	370
Other income	-	-	1,895	2,239
Core income	531,508	593,882	255,664	302,131
Project income	<u>-</u>	<u>-</u>	<u>52,557</u>	<u>62,109</u>
	<u>531,682</u>	<u>594,077</u>	<u>339,577</u>	<u>401,294</u>
Total incoming resources	559,965	625,679	366,203	432,759
EXPENDITURE				
Charitable activities				
Members meeting	7,246	8,096	38,052	44,968
Administration Board	22,105	24,699	31,991	37,805
PDG think tank	-	2,566	2,171	2,566
Website	9,690	10,827	7,922	9,362
Parkinson's life	72,009	80,460	58,392	69,005
Exhibitions	1,539	1,720	12,999	15,362
Communications	14,185	15,850	10,050	11,877
Social Media	6,629	7,407	20,470	24,190
Digital strategy	6,083	6,797	10,228	12,087
Member organisation outreach	10,273	11,479	11,934	14,103
GDPR	540	603	1,076	1,272
PDCS	2,946	3,292	28,089	33,194
Research/clinical trials	3,331	3,720	1,550	1,832
Parkinson's info	2,836	3,169	2,748	3,247
Data collection	131	146	1,812	2,141
Global campaign	-	-	2,404	2,841
Treat ER	8,220	9,185	250	295
EYOPD	2,231	2,493	2,380	2,813
Advocacy	161,744	180,725	1,877	2,218
AirLiquide carers project	4,066	4,543	28,557	33,747
Adviser	16,194	18,094	1,547	1,828
Prevalence	302	337	-	-
Merz (survey/HCP awareness)	3,017	3,371	-	-
Medtronic Awareness projects	309	345	-	-
HCP info/education materials	249	278	-	-
Carried forward	355,875	397,638	276,499	326,753

This page does not form part of the statutory financial statements

European Parkinson's Disease Association

Statement of Financial Activities for the Year Ended 31st December 2020

Charitable activities

Brought forward	355,875	397,638	276,499	326,753
Awareness campaigns	2,202	2,460	-	-
Brain life goals	176	197	-	-
Bial's	3,630	4,056	-	-
Servier patient insights works	2,838	3,171	-	-
Kyowa kirin	289	323	-	-
Abbott	39	44	-	-
AbbVie	228	255	-	-
Boston affiliates	18	20	-	-
Britannia (awareness)	507	566	-	-
CMS	2,208	2,467	-	-
EPDA industry meeting	2,048	2,288	-	-
Industry partnered projects	3,177	3,550	-	-
Medtronic partnered project	147	164	-	-
NeuroPath EU project	612	684	-	-
Parkinson sleep project	2,166	2,420	-	-
Parkinson's games	1,074	1,200	-	-
Sunovion research project	3,346	3,739	-	-
Tshipi's art exhibition	318	355	-	-
WPC Barcelona	<u>4,938</u>	<u>5,517</u>	-	-
	385,836	431,115	276,499	326,753

Other

Rent	1,326	1,482	-	-
------	-------	-------	---	---

Support costs

Management

Advertising	3,142	3,511	-	-
Fundraising	<u>5,637</u>	<u>6,299</u>	-	-
	8,779	9,809	-	-

Finance

Wages	25,099	28,044	8,693	10,273
Bank charges	178	199	-	-
Financial administration	30,818	34,435	15,326	18,112
Accountancy fees	5,000	5,587	4,760	5,625
Bookkeeping costs	<u>4,000</u>	<u>4,469</u>	-	-
	65,095	72,734	28,779	34,010

Other

General expenditure	12,714	14,206	13,062	15,436
Administration costs	<u>44,918</u>	<u>50,189</u>	<u>8,436</u>	<u>9,969</u>
	57,632	64,395	21,498	25,405

Governance costs

Independent examination costs	1,000	1,117	1,000	1,182
-------------------------------	-------	-------	-------	-------

European Parkinson's Disease Association

**Statement of Financial Activities for
the Year Ended 31st December 2020**

Total resources expended	<u>519,668</u>	<u>580,653</u>	<u>342,702</u>	<u>404,988</u>
Net income before gains and losses	40,297	45,026	23,501	27,772
Realised recognised gains and losses				
Realised gains/(losses) on fixed asset investments	<u>(7,729)</u>	<u>(8,636)</u>	<u>(2,285)</u>	<u>(2,700)</u>
Net income	<u>32,568</u>	<u>36,390</u>	<u>21,216</u>	<u>25,072</u>

European Parkinson's Disease Association

**Statement of Financial Position for
the Year Ended 31st December 2020**

	2020 (£)	2020 (€)	2019 (£)	2019 (€)
CURRENT ASSETS				
Debtors	133,500	149,167	68,704	81,191
Cash at bank and in hand	<u>457,222</u>	<u>510,879</u>	<u>411,317</u>	<u>486,074</u>
	590,722	660,045	480,021	567,265
CREDITORS				
Amounts falling due within one year	(255,475)	(285,456)	(177,342)	(209,574)
NET CURRENT ASSETS	<u>335,247</u>	<u>374,589</u>	<u>302,679</u>	<u>357,691</u>
TOTAL ASSETS LESS CURRENT LIABILITIES	335,247	374,589	302,679	357,691
NET ASSETS				
FUNDS				
Unrestricted funds	11,650	13,017	124,112	146,669
Restricted funds	<u>323,597</u>	<u>361,572</u>	<u>178,567</u>	<u>211,022</u>
TOTAL FUNDS	<u>335,247</u>	<u>374,589</u>	<u>302,679</u>	<u>357,691</u>